1

November 28th - 30th • Windsor Barra Hotel

Rio de Janeiro/Brazil

7th LACTRIMS 2012Latin American Congress of Multiple Sclerosis

5th ANERJ CONGRESS

2 3

MStrength.MScience.

www.genzyme.comwww.msatrium.com

We welcome you to the LACTRIMS Congress 2012. Visit our booth.

The strength of unprecedentedscience. The strength of theMS community. The strengthof our commitment.

LACTRIMS - RIO 2012 PRESIDENT MESSAGE

Dear colleagues, We are announcing the FINAL PROGRAM of the VII LatinAmerican Congress of Multiple Sclerosis, to be held on 28-30 November 2012, in the city of Rio de Janeiro. It will gather together in Brazil the most important Latin-American specialists that investigate, treat and research Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO).

The clinical and laboratorial characteristics of the Idiopathic Inflammatory Demyelinating Diseases of the Central Nervous System in the Latin-American population, the prevalence of these diseases in different latitudes of the extensive geographical area, which extends from the frontiers of Mexico to Patagonia, and the environmental and biological factors related to this prevalence, will be the main themes of the Congress. These themes have been arousing a growing interest in the international scientific community and will be a part of the plenary sessions and the round-table discussions with Latin-American specialists selected for their scientific production.

The program is divided into plenary sessions, round-table discussions, oral presentations and sessions for the oral presentation of the posters.

The 19 plenary sessions will be held in the morning, in a single auditorium, with themes about the current state of knowledge and the characteristics of MS and NMO in Latin America. These will be presented by Latin-American specialists who have been identified for their scientific production. Some of these specialists work in the USA, Canada and Europe, where they are the leaders in different fields of knowledge: Sergio Baranzini (USA), Marcelo Kremenchutzky (Canada), Raul Mandler (USA), Victor Rivera (Houston) and Oscar Fernandez (Spain). One of the speakers on NMO will be Professor Jun-ichiKira (Japan), who is the most important researcher on

the optic-spinal form of Asiatic Multiple Sclerosis.

In the afternoon, round-table discussions, courses and oral presentations will be held in four auditoriums.

Three courses of continuous education are programed. Update in multiple sclerosis for all health area staff, Methods of epidemiological research for participants who want to carry out research, and last but not least, a neuro immunology course for specialists in demyelinating diseases.

In five Satellite Symposiums, the current and future treatment of Multiple Sclerosis will be addressed by Latin-American and European specialists.

More than two hundred original studies have been accepted for poster or oral presentation. This will demonstrate the advance of research in poster sessions and oral presentation, disclosing the Latin-American experience in research.

LACTRIMS – RIO 2012 will award prizes for the best works of young researchers and the best posters. Furthermore, it will award prizes for the best publications of studies performed in Latin America between 2010 and 2012.

LACTRIMS – RIO 2012 is designed to strengthen the bonds of friendship between specialists, for the disclosure of research, and the integration of groups for the amplification of Latin-American scientific production in the near future.

Finally a special thanks to all the sponsors that, ethically and friendly made possible the organization of this Congress

Regina Maria Papais AlvarengaLactrims Congress President

4 5

ANERJ PRESIDENT MESSAGE

Dear colleagues,

It is with great satisfaction that we are holding our V

Congressof Neurology of Rio de Janeiro, to be held

this year in partnership with the VII Latin-American

Congress of Multiple Sclerosis (7thLACTRIMS), at

the pleasant and attractive Hotel Windsor Barra

on 28,29 and 30 November. Important names from

Brazilian and world neurology will be present at

both the Congresses, which I am sure will be of

enormous benefit for everyone. Furthermore, we

must highlight this positive opportunity to meet

again with countless colleagues and friends. This

always translates into agreeable and profitable

encounters, interchanges, and exchanges of

experiences.

As has already been communicated by our Secretary

and/or by Interevent, our special partnership,

associates of ANERJ will have a significant discount

when they participate in the two Congresses. The

registration should be made through Interevent

as quickly as possible. Please remember that

this discount is only available to members who

have paid their 2012 membership. After some

important work with Banco Santander, and after

having resolved some outstanding administrative

matters, we are able to offer payment via boleto-

identificado, which facil itates the work and control

of payments. We are sending the boletos for the

membership via email for those who have not yet

made the payment. You can become an associate

or re-register by using the website: www.anerj.

org.br. If you have already paid, please ignore this

message.

On Thursday, 29 November, at the end of the day’s

activities, all the members are invited to our General

Meeting. In this, we will have the opportunity to

present, among other points, some results referring

to the ongoing work of the executive board, which

has been achieved through the collaboration of

everyone, great effort and determination. It is

important to highlight the situation of our new

ANERJ website, with its domain name, hosting

and password. The website offers several social

services, for which we rely on your participation.

It also provides an excellent opportunity to express

all your thoughts. Please send your suggestions on

how to improve ANERJ.

I hope that you all benefit from these two

Congresses that ANERJ has the pleasure to offer

to its associates.

José Mauro Braz de Lima

ANERJ President

Merck Serono é umadivisão da Merck

Merck Serono:science that changes lives

Merck Serono. Over 300 years of tradition,

not only among the professionals in

charge of improving people’s health,

but also among all those who have had

access to its innovating therapies.

Merck Serono’s neurodegenerative

diseases division is working hard

in innovation, and not only for one

biotechnological product showing

our galenic know-how, but rather the

development of new treatment options

and devices, as well as advanced

support services for those stricken with

those diseases. Also considering the

possibilities of scientific development and

improvement for the medical community,

Merck Serono provides several projects

for continued medical education, and

grants incentives for existing educational

projects, publication of scientific papers,

and opportunities for specialization in

major international institutions.

In this important relationship, Merck

Serono is proud of having you as an ally

in the search for a better quality of living

for thousands of patients.

2222/2012 - nov 2012

Anúncio 'Merck Neurologia'.indd 1 11/8/12 11:24 AM

6 7

INDEX

General Information 8

Conference Organization 10

International Speakers 11

National Speakers 13

Map 16

Courses 18

Overview Programme 20

Scientific Program 25

ANERJ Scientific Program 40

Index 48

Oral Presentation 56

E- Poster Presentation ANERJ 58

E- Poster presentation LACTRIMS 64

8 9

GENERAL INFORMATION

Organized by

Conference Secretariat:

Avenida das Américas, n° 3500 | Sala 405 | Bloco Hong Kong 3000

Barra da Tijuca | Rio de Janeiro | Zipcode: 22640-102

Phone: 55 21 3326 3320 | Fax: 21 2437 1483 | Website: www.interevent.com.br

Venue Address

Avenida Lucio Costa, n° 2630 | Barra da Tijuca

Rio de Janeiro | Zipcode: 22620-170

Phone: 55 21 2195 5000 | website: www.windsorhoteis.com.br

Travel Agency

Rua Barão de Ipanema, n° 56 - 3° andar

Copacabana | Rio de Janeiro | Brazil

Phone: 55 21 3265 8882 I Fax: 21 2540 8794 I Website: www.bec-eventos.com.br

Latin-American Committee for Treatment and Research

in Multiple Sclerosis.

Associação de Neurologia do Estado do Rio de Janeiro

Information for SpeakersPlease bring your presentation to the Speakers Room at least 2 hours before your presentation. Speakers

Room: open from 08:00 AM to 07:00 PM

A technician will assist you in transferring the presentation to a central conference server. When the

transfer is complete, the technician performs a quick run of the presentation in order for you to check

whether the presentation runs correctly and that all parts of the presentation are copied.

Please bring your presentation on CD, DVD or memory stick.

HeadsetsPlease collect the headset receivers for simultaneous translation at the headset desks located by the

entrances to the session rooms where translation is provided.

Headsets can be returned right after the session or can be kept during the day. Headsets must be

returned each afternoon before you leave the conference center.

CNAThis congress is certified by CNA - Comissão Nacional de Acreditação.

Participants who are able and registered in CNA and wish to receive the credits should fil l at the form at

the conference secretariat.

Score for all specialties: 10 points

BadgeThe use of the badge will be required in all scientific activities and to access the exhibit area.

There will be 02 categories: prescribers and non-prescribers, so that exhibitors can deliver materials to

the appropriate category.

Prescribers: doctors and residents

Non-prescribers: other health professionals and students.

Lost and FoundFound items should be returned to the conference secretariat. If you lose something, please report to

the conference secretariat for assistance.

10 11

LACTRIMS INTERNATIONAL COMMITTEE

Regina Maria Papais Alvarenga Lactrims 2012 President

Soniza Vieira Alves LeonPresident of the Scientific Committee

Jorge Nogales-Gaete Lactrims’s President

Miguel Angel MaciasLactrims’s Vice President

Claudia CárcamoLactrims’s Secretariat

Violeta DiazLactrims’s Treasurer

Fernando Hammuy Pro Tesoureiro

Fernando Gracia Vocal Titular

Miguel Córdova Vocal Titular

José Cabrera-Gómez

Vocal Titular

Patricio AbadVocal Suplente

Orlando Garcea

Vocal Suplente

ANERJ COMMITTEE

José Mauro Braz de Lima

Maria Clinete Sampaio Lcativa

Antonio Luiz dos Santos Werneck Neto

Regina Maria Papais Alvarenga

Ana Maria Yamada

Marco O Py

Marli Pernes

Solange Dultra

Ana Cristina Cabral de Lima

Ana Claudia C B Leite

COMMITTEE INTERNATIONAL SPEAKERSDenisa Hurtukova

Edgard Rojas Huerto

Edgardo Cristiano

Edgardo Reich

Elizabeth Armas

Fernando Caceres

Fernando Gracia

Fernando Hamuy Díaz De Bedoya

Freda Hernández

Guillermo Gómez

Guillermo Izquierdo

Hans-Peter Hartung

Ibis Soto

Jaime Toro

Jenner Velásquez

Jill Conners

Adriana Carra

Alexander Parajeles

Alina G.quevedo

Ana Lucia Rosso

Andres Villa

Arnoldo Soto

Carlos A. Díaz Manzano

Carlos Cuevas

Carlos Ketzoian

Carlos Oehninger

Cesar Caparo

Christian Naurath

Claudia Cárcamo

Daniel Amitrano

Daniela Pohl

Darwin Vizcarra

12 13

Sergio Baranzini

Silvia Tenembaum

Teresa Corona

Victor Rivera

Violeta Diaz

Vladmiro Sinay

Walter A Rocca

Yara Ganeo

John Richert

Jorge Barahona

Jorge Correale

Jorge Nogales-Gaete

Jose A Cabrera Gomez

Juan Carlos Alcantara

Juan Garcia Bonitto

Juan Pablo Princich

Jun-Ichi Kira

Lilia Nunez Orozco

Liliana Patrucco

Marcelo Kremenchutzky

Mario O. Melcon

Mario Rivera Kindel

Miguel Angel Macias

Miguel Córdova Ruiz

Nancy Richert

Orlando Garcea

Oscar Fernandez

Oscar Gonzales Gamarra

Patricio Abad

Pedro Cabello

Raul Arcega

Raul Mandler

Ricardo Buzó

Rivera Flores

Roberto Rotta Escalante

NATIONAL SPEAKERS

Carmen Antão Paiva

Celmir De Oliveira Vilaça

Charles Peter Tilbery

Cláudia Cristina Ferreira Vasconcelos

Claudio Heitor Gress

Cleonice Bento

Cristiana Caires

Cristiana Goes

Cristiane Afonso

Cristiane Marins

Damácio Ramon Kaimen Maciel

Daniel Amitrano

Daniel Paes De Almeida Dos Santos

Denise Nicaretta

Denise Sisterolli Diniz

Doralina Guimarães Brum Souza

Douglas Goodin

Eduardo Davidovich

Eduardo Prezzi

Eliana Maranhão

Eliasz Engelhardt

Elizabeth Batista

Elizabeth Regina Comini Frota

Elza Dias Tosta da Silva

Abelardo De Queiroz C. Araújo

Adailton Pontes

Adriano Miranda

Alberto Alan Gabbay

Alfredo Damasceno

Amilton Antunes Barreira

Ana Beatriz Calmon Nogueira Da Gama

Ana Claudia C. Leite

Ana Cristina Cabral de Lima

Anderson Kuntz Grzesiuk

André Matta

Andre Muniz

Angelo Maiolino

Antonio Gomes Neto

Antonio Luiz Werneck

Arthur Padão Gosling

Benito Damasceno

Bernardo Liberato

Bruno Castelo Branco

Bruno Coutinho

Camila Pupe

Camila Rodrigues

Carla Quero

Carlos Henrique Melo Reis

14 15

Joseph Brooks

Leila Chimelli

Leonardo de Deus Silva

Leticia Fezer

Lucia Fontenelle

Luiz Claudio Thuler

Luiz Domingos Mendes Melges

Luiz Felipe Vasconcellos

Mônica Koncke Fiuza Parolin

Marcelo Cagy

Marcio Bezerra

Marco Antonio Araújo Leite

Marco Antonio Sales Dantas De Lima

Marco Oliveira Py

Marco Tulio Medina

Marcos Papais Alvarenga

Marcus Tulius T. Silva

Maria Cecília de Vecino

Maria Clinete Sampaio Lacativa

Maria Cristina Del Negro Barroso Freitas

Maria Eugênia Tejada Ocampo

Maria Fernanda Mendes

Maria Lúcia Brito Ferreira

Maria Lúcia Vellutini Pimentel

Maria Lucia Mendonça

Mariana Spitz

Marina Alvarenga

Emerson Gasparetto

Ernani Maciel

Fabíola Rachid Malfetano

Fernanda Erthal

Fernanda Guimarães

Fernanda Moll

Fernanda Pereira

Fernanda Rueda Lopes

Fernando Faria De Andrade Figueira

Fernando Mendonça

Flavio Henrique De Rezende Costa

Gabriel Paiva Da Silva Lima

Giseli Quintanilha

Greice Cardoso De Carvalho Silva

Gustavo Adolfo Rodrigues Valle

Helcio Alvarenga

Helcio Alvarenga Filho

Helio Teive

Heloise Helena de Figueiredo Siqueira

Henry Pereira Da Silva

Isabella Guedes

Jefferson Becker

João Gabriel Dib Farinhas

João Santos Pereira

José Maurício Godoy

José Vicente Martins

Jose Mauro Braz De Lima

Marleide Gomes

Marli Pernes

Marzia P. Sohler

Maurice Vincent

Norma Fleming

Osvaldo Nascimento

Péricles Maranhão-Filho

Palmiro Torrieri Júnior

Patricia Beatriz Christino Marinho

Raphael Breder

Regina Papais Alvarenga

Renata Paes

Ricardo Canuto

Ricardo Turon

Rodrigo Barbosa Thomaz

Rossano Cabral De Lima

Sebastião Eurico

Silvio Pessanha Neto

Solange Vianna Dultra

Soniza Vieira Alves Leon

Soraya Pulier

Suzana Costa Nunes Machado

Tamara Checcacci

Tania Regina D. Saad Salles

Tarso Adoni

Valéria Coelho Santa Rita Pereira

Yara Dadalti Fragoso

Verônica Brandão

Walter Oleschko Arruda

16 17

MAP

18 19

COURSES

COURSE 01ReseaRch Methods aPPlied to MultiPle scleRosis

Date: November 28th

Time: 14:00pm to 16:00pm

Room: SEGÓVIA II

Secretary: Juliane Sauter Dalter | Coordenador: CARLOS KETZOIAN

COURSE 02uPdate - MultiPle scleRosis FoR all

Date: November 29th

Time: 14:00pm to 16:00pm

Room: SEGÓVIA II

TIME PROGRAM Speaker

14:00 - 14:45 Introduction to study design: With examples from multiple sclerosis Walter A. Rocca

14:45 - 15:15 Acuity of the EM diagnosis in neuroepidemiological studies Violeta Diaz

15:15 - 15:45 Capture and recapture application method Mario O. Melcon

15:45 - 16:15 Studies on risk factors in MS Luiz Claudio Thuler

TIME PROGRAM Speaker

14:00 - 14:20 The concept and classification of demyelinating diseases Fabiola Rachid

14:20 - 14:40 Multiple Sclerosis Diagnostic Criteria Liliana Patrucco

14:40 - 15:00 Clinical Isolated Syndrome Roberto Rotta Escalante

15:00 - 15:20 MRI for MS Diagnosis Emerson Gasparetto

15:20 - 15:40 Inflammation and degeneration in MS Goodin

15:40 - 16:00 Treatments Algoritms In MS Carlos Cuevas

COURSE 03NeuRoiMMuNoloGY oF idioPathic iNFlaMMatoRY deMYeliNatiNG diseases

Date: November 30th

Time: 14:00pm to 16:00pm

Room: SEGÓVIA II

TIME PROGRAM Speaker

14:00 - 14:10 Neuroimmunology up to date Andres Villa

14:10 - 14:40 Immunological and pathological features of neuromyelitis optica JUN-ICHI KIRA

14:40 - 15:10 Neuroimmunology of MS Jorge Correale

15:10 - 15:35 Experimental Allergic Encephalitis Alessandro Farias

15:35 - 16:00 TH 17 Cleonice Bento

20 21

QUARTA-FEIRA, 28/11/2012Horário Segóvia I Segóvia II Segóvia III Segóvia IV - ANERJ Oriente

08:00 - 10:00 PleNaRY sectioN

09:00 - 10:00 PleNaRY sectioN Movement disorders

10:00 - 10:30 coFFe-BReaK

10:30 - 11:10 PleNaRY sectioN Movement disorders - Part 2

10:30 - 12:00 the state of the art in Ms

11:10 - 12:30 PleNaRY sectioN coGNitioN

12:30 - 13:30involuntary Movements : clinic and botulinum toxin treatment

with eNMG

12:30 - 14:00 NoVaRtis satellite symposium Growing evidence once-daily oral fingolimod in Ms

14:00 - 16:00 Ms treatmentcourse - Research Methods

applied to Mschildren demyelinating diseases epilepsy iidd in latin america

16:00 - 16:30 coFFee BReaK

16:30 - 18:30 Future Ms treatments Neuroepidemiology in MsGenetic and Familiar Ms and

MNo

Rehabilitation and Neurophysiology -

Neuroinfectioniidd in latin america

18:30 - 19:30 opening symposium - alcohology

19:00 - 20:30 simpósio teVa - sharpening the Management of Ms

QUINTA-FEIRA, 29/11/2012Horário Segóvia I Segóvia II Segóvia III Segóvia IV - ANERJ Oriente

08:00 - 09:00 Jean Martin charcot section

09:00 - 10:00 What is Ms and What is Not Ms Peripheral Neuropathy and Pain

10:00 - 10:30 coFFee BReaK

10:30 - 11:10 PleNaRY sectioNPeripheral Neuropathy and Pain

- Part 2

10:30 - 12:00 Ms in latin america and canada

11:10 - 12:30 PleNaRY sectioN Neuropediatrics

12:30 - 14:00 Biogen idec symposium : commitment to treatments of demyelinating and Neurodegenerative diseases

14:00 - 16:00 Pit Falls in Ms diagnosis course - update Ms For all Fatigue Motor Neurone iidd in latin america

16:00 - 16:30 coFFee BReaK

16:30 - 18:30 challenges in Msupdate in Methods of

investigationcognition iidd in latin america

16:30 - 18:00 Neurommunology

18:00 - 19:00 aNeRJ General assembly

18:30 - 20:00 simpósio MeRcK

OVERVIEW PROGRAMME

22 23

SEXTA-FEIRA, 30/11/2012Horário Segóvia I Segóvia II Segóvia III Segóvia IV - ANERJ Oriente

08:00 - 10:00 PLENARY SECTION

09:00 - 10:00 Neuromyelitis Optica Headache

10:00 - 10:30 COFFEE BREAK

10:30 - 10:50 PLENARY SECTION Headache - Part 2

10:30 - 12:00 Neuromyelitis Optica

10:50 - 12:30 PLENARY SECTION History of Medicine

12:30 - 14:00 Bayer Symposium - Impact of MS on Survival and the Role of Interferon β 1-B

12:50 - 13:50 Biogen Idec Conference

14:00 - 16:00 Hot Topics Course - Neuroimmunology of IIDDAdvances in Symptomatic

TreatmentCerebrovascular Diseases Clinical Trials and Guidelines

16:00 - 16:30 coFFee BReaK

16:30 - 18:30 Helcio Alvarenga Award Research in IIDD LACTRIMS Oral Presentation MS Neurointensive Treatment Latin American Committee

18:30 - 19:30 LACTRIMS AND ANERJ CLOSURE SECTION

24 25

QUANTO ANTES MELHOR11,12

• COPAXONE® Does not interfere with the immunological surveillance2,3, differing from immunosupressant drugs that are used in the MS therapy4,8.

• COPAXONE®, Improvement of spasticity can be noted in the first months of treatment9

• COPAXONE® Increased the Quality of Life by 40% in treatment-naive patients in the first 6 months of therapy 10

Copaxone®:FirstchoiceinMStherapy1

Referências: •1.Ministério da Saúde, 2010: DOU 24/09/2010; Portaria nº 493/2010•2.Weber MS, et al. Neurotherapeutics. 2007;4(4):647-653. 2. COPAXONE® prescribing information. Teva Neuroscience, Inc. •3.Aharoni R et al. PNAS. 2008: 105: 11358-63•4.Mundel T. FTY_AAN May 1, 2009•5.Chun J, et al. Clin Neuropharm. 2010;33(2):91-101.•6.Lopez-Diego RS, et al. Nat Rev Drug Discovery. 2008;7(11):909-920. •7.Kappos L, et al. N Engl J Med. 2010;362(5):387-401.•8.Cohen JA, et al. N Engl J Med. 2010;362(5):402-415.•9.Jongen P.J., at al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health and Quality of Life Outcomes 2010, 8:133.•10. Meca-Lallana JE. Balseiro JJ. Et al. Spasticity improvement in patients with relapsing-remittingmultiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. J Neurol Sci. 15;315(1-2):123-8.2012.•11. Miller JR. J Manag Care Pharm. 2004; 10(3)(Suppl B): S4-S11.•12. Mikol DD et al., Lancet Neurol. 2008 Oct;7(10):903-14.CÓ

D. A

NCO

07.11

.12 no

vem

bro/

2012

Contra-indicações: o produto está contra-indicado para pacientes com hipersensibilidade conhecida ao acetato de glatirâmer ou manitol.Interações medicamentosas: interações entre o COPAXONE® (acetato de glatirâmer) e outras drogas não foram completamente avaliadas.

COPAXONE® (acetato de glatirâmer) - solução injetável - uso subcutâneo 20mg/mL - USO ADULTO - Indicações: Reduzir a freqüência de recidivas nos pacientes com esclerose múltipla remissiva recidivante (EMRR). Ainda não existem estudos comprovando o benefício do COPAXONE® em outras formas de Esclerose Múltipla. Também é indicado no tratamento de pacientes que tiveram um primeiro episódio clínico bem definido e que apre-sentem alto risco de desenvolver a esclerose múltipla clinicamente definida (EMCD). Contra-indicações: O produto está contra-indicado para pacientes com hipersensibilidade conhecida ao acetato de glatirâmer ou manitol. Advertências e Precauções: A administração deve ser feita exclusivamente por via subcutânea. Não deve ser administrado por via intravenosa; os pacientes devem ser instruídos sobre técnicas de auto-administração da injeção de COPAXONE® para garantir a segurança da administração. Baseado nos dados atuais, não é necessário nenhuma precaução especial para pacientes envolvidos em atividades que requerem alerta mental, como dirigir veículos ou operar máquinas. Como o acetato de glatirâmer pode modificar a resposta imunológica, deve-se considerar a possibilidade de que ele possa interferir com a função imunológica. Gravidez e lactação: Categoria B de risco na gravidez. Interações medicamentosas: Interações entre o COPAXONE® e outros fármacos não foram completamente avaliadas. Reações Adversas: Reações adversas mais comumente observadas: reações no local de aplicação, vasodilatação, dor no peito, astenia, infecção, dor, náusea, artralgia, ansiedade e hipertonia. Posologia: a dose recomendada para adultos para o tratamento de esclerose múltipla remissiva recidivante é de 20 mg/dia injetada subcutaneamente. VENDA SOB PRESCRIÇÃO MÉDICA. Reg. MS 1.5573.0001. Farm. Resp.: Mônica Riyoko Nekozuka – CRF-SP n° 16.970. Teva Farmacêutica Ltda. A persistirem os sintomas, o médico deve ser consultado. Documentação Científica e informações adicionais estão à disposição da classe médica, mediante solicitação.*CIS: Síndrome Clínica Isolada. Copaxone possui indicação em bula.

LACTRIMS SCIENTIFIC PROGRAM

26 27

November 28th

08:00 - 10:00 | Plenary SessionRooM seGÓVias

Chair: Jorge Nogales-Gaete

Secretary: Suzana Costa Nunes Machado

08:10 - 08:30 - Opening: Latin America

Keynote Speaker: Victor Rivera

08:30 - 09:00 - The impact of the published papers: What do they say about Demyelination Inflammatory

Idiopathic Diseases in Latin America?

Speaker 1: Regina Papais Alvarenga

09:00 - 09:30 - MS Prevalence in Latin America

Speaker 2: Mario O. Melcon

09:30 - 10:00 - The environmental factors influencing MS immunology mechanism in Latin American

Speaker 3: Jorge Correale

10:00 - 10:30 | Coffee Break

10:30 - 12:00 | Plenary Session - The State of the art in Multiple SclerosisRooM seGÓVias

Chair: Soniza Vieira Alves Leon

Secretary: Damácio Ramon Kaimen Maciel

10:30 - 11:00 - Mapping genetic susceptibility and modeling pathogenesis in multiple sclerosis

Speaker 1: Sergio E Baranzini

11:00 - 11:30 - The role of the Blood Brain Barrier in Multple Sclerosis

Speaker 2: Andres Villa

11:30 - 12:00 - Epidemiology of multiple sclerosis: The need to integrate new approaches to its reality

Speaker 3: Oscar Fernandez

12:30 - 14:00 | Novartis Symposium Growing evidence once-daily oral fingolimod in MSRooM seGÓVias

12:30 - 12:40 | Welcome and introduction

Speakers: Soniza Vieira Alves Leon & Nadina Frider

12:40 - 13:10 | Scientific paradigms in MS – Burden of disease and unmet needs

Speaker: Jaume Sastre Garriga

13:10 - 13:40 | Growing evidence for the benefit–risk profile of treatment with fingolimod

Speaker: Heinz Wiendl

13:40 - 13:55 | Q&A (clinical cases)

Speaker: Soniza & Speakers

13:55 - 14:00 | Closing remarks ECTRIMS slides

Speaker: Soniza Vieira Alves Leon

14:00 - 16:00 | Activities - Idiopathic Inflammatory Demyelinating Diseases (IIDD) in Latin AmericaRooM oRieNte

Chair: Regina Papais Alvarenga

Secretary: Erlane Fernandez

14:00-14:15 -The IIDD spectrum in Latin America

Speaker 1: Regina Alvarenga

14:15-14:30 - IIDD in Central America

Speaker 2: Fernando Gracia

14:30 - 14:45 - IDD in Mexico

Speaker 3: Rivera Flores

14:45 - 15:00 - IIDD in Venezuela

Speaker 4: Ibis Soto

15:00 - 15:15 - IIDD in Peru

Speaker 5: Cesar Caparo

15:15 - 16:00 - Oral Presentation

15:15 - 15:30 - A 63 - Geographical Distribution of Patients With Multiple Sclerosis treated with

Immunomodulator at Public Healthy System in Chile, 2008-2012

Authors: Jorge Elías Nogales-Gaete;Casandra Ivonne Araya Salfate; Claudio Alonso Eloiza Concha; Luis Rodrigo

Aracena Conte; María Lorena Acevedo González; Paula Carolina Agurto Merino; Séfora Esperanza Martínez

Espinoza; Sergio Omar Cepeda Zumaeta; Silvia Jazmín Labbé Rojas;Vannia Fernanda Díaz Zamorano.

15:30 - 15:45 - A 62 - Genetic variability in Peruvian patients with relapsing remitting multiple sclerosis,

using STR markers DYS390, DYS391, DYS392 Y chromosome

Authors: Miguel Ernesto Cordova Ruiz

15:45 - 16:00 - A 95 - Research Methods applied to Multiple Sclerosis - Neuromyelits Optica and Multiple

Sclerosis: a view from DNA, RNA and protein profiles

Authors:Giselle Penton-Rol;Marcelo Nazabal-Galvez;Hanlet Camacho-Rodríguez;Seydi Pedroso-Santana;Seydi Pedroso-

Santana;Majel Cervantes- Llanos; Alberto Cintado- Benítez;Mayte Ale-Martínez;Adelaida Villarreal-Barrios;Tamara

Díaz-Argudín;Jesus Benítez-Fuentes;Nancy Pavón-Fuentes;Daymet Grass;Jose Antonio Cabrera-Gómez.

Speaker: Mario O. Melcon

14:00 - 14:30 | Round Table - Multiple Sclerosis Treatment: Special topics with speakers defending the agreement or not agreement MS treatment approachesFyngolimod - 1st line therapy x 2nd line therapyRooM seGÓVia i

Chair: Edgardo Cristiano

Secretary: Isabella D´Andrea Meira

14:00 - 14:15 - Fyngolimod 1st line therapy

Speaker 1: Orlando Garcea

14:15 - 14:30 - Fyngolimod 2nd line therapy

Speaker 2: Edgardo Cristiano

14:00 - 16:00 | Course - Research Methods applied to Multiple SclerosisRooM seGÓVia ii

Coordinator: Carlos Ketzoian

Secretary: Juliane Sauter Dalter

14:00 - 14:45 - Introduction to study design: With examples from multiple sclerosis

Speaker: Walter A Rocca

14:45 - 15:15 - Acuity of the MS diagnosis in neuroepidemiological studies

Speaker: Violeta Diaz

15:15 - 15:45 - Capture and recapture application method

28 29

15:45 - 16:15 - Studies on risk factors in MS

Speaker: Luiz Claudio Thuler

14:00 - 16:00 | Round Table - Children Demyelinating diseasesRooM seGÓVia iii

Chair: Silvia Tenembaum

Secretary: Tania Regina D. Saad Salles

14:00 - 14:30 - ADEM and NMO in children

Speaker 1: Freda Hernández

14:30 - 15:00 - MRI in the differential diagnosis of pediatric demyelinating disorders

Speaker 2: Juan Pablo Princich

15:00 - 15:30 - Pediatric MS

Speaker 3: Daniela Pohl

15:30 - 16:00 - Treatment of pediatric demyelinating disorders

Speaker 4: Silvia Tenembaum

14:30 - 15:00 | Round Table - Multiple Sclerosis Treatment: Special topics with speakers defending the agreement or not agreement MS treatment approachesNon responders to IFN BETA or Glatiramer Acetate - switch to what?RooM seGÓVia i

14:30 - 14:45 - Switch one immunomodulator to other

Speaker 3: Adriana Carra

14:45 - 15:00 - Switch to Natalizumab

Speaker 4: Rodrigo Barbosa Thomaz

15:00 - 15:30 | Round Table - Multiple Sclerosis Treatment: Special topics with speakers defending the agreement or not agreement MS treatment approachesNatalizumab x Fingolimode for severe MSRooM seGÓVia i

15:00 - 15:15 - Natalizumab

Speaker 5: Marcos Papais Alvarenga

15:15 - 15:30 - Fingolimod

Speaker 6: Jefferson Becker

15:30 - 16:00 | Round Table - Multiple Sclerosis Treatment: Special topics with speakers defending the agreement or not agreement MS treatment approachesMS treatment Withdrawal - Is it Possible?RooM seGÓVia i

15:30 - 15:45 - YES!

Speaker 7: Charles PeterTilbery

15:45 - 16:00 – NO!

Speaker 8: Fernando Faria de Andrade Figueira

16:00 - 16:30 | Coffee Break

16:30 - 18:30 | Round Table - Idiopathic Inflammatory Demyelinating Diseases (IIDD) in Latin AmericaRooM oRieNte

Chair: Arnoldo Soto

Secretary: Melina Bernardes

16:30 - 16:50 - IIDD in Argentina

Speaker 1: Adriana Carra

16:50 - 17:10 - IIDD in Colombia

Speaker 2: Juan Garcia Bonitto

17:10 - 17:30 - IIDD in Paraguay

Speaker 3: Fernando Hamuy Díaz de Bedoya and Sara Florentin

17:30 - 17:50 - IIDD in Chile

Speaker 4: Claudia Cárcamo

17:50 - 18:10 - IIDD in Uruguay

Speaker 5: Carlos Oehninger

18:10 - 18:30 - IIDD in Bolivia

Speaker 6: Maria Eugênia Tejada Ocampo

16:30 - 18:30 | Round Table - Future Multiple Sclerosis Treatments

RooM seGÓVia i

Chair: Helcio Alvarenga

Secretary: Vanderson Carvalho Neri

16:30 - 17:00 - Autologus STEM CELL transplantation in MS

Speaker 1: Amilton Antunes Barreira

17:00 - 17:30 - Steam Cell Therapy in Multiple Sclerosis

Speaker 2: Oscar Fernandez

17:30 - 18:00 - Teriflunomide: Targeting Activated Lymphocyte Proliferation

Speaker 3: Victor Rivera

18:00 - 18:30 - Alemtuzumab: Targeting Circulating Lymphocytes by Selective Depletion

Speaker 4: Guillermo Izquierdo

16:30 - 18:30 | Round Table - Neuroepidemiology in MS: Latin American Studies

RooM seGÓVia ii

Chair: Walter A Rocca

Secretary: Heloise Helena de Figueiredo Siqueira

16:30 - 16:45 - Neuroepidemiology in MS: Infections e MS

Speaker 1: Tereza Corona

16:45 - 17:00 - Association Between The Prevalence of MS And Environmental Factors In Latin America

And The Caribbean: An Ecological Study (GEEMAL: Grupo Colaborativo Multicéntrico para el Estudio

de la Esclerosis Múltiple en América)

Speaker 2: CARLOS KETZOIAN

17:00 - 17:15 - Epidemiological MS in Chile

Speaker 3: Violeta Diaz

30 31

17:15 - 17:30 - Pregnancy and MS

Speaker 4: Yara Dadalti Fragoso

17:30 - 17:45 - Epidemiological MS in Cuba

Speaker 5: Jose A Cabrera Gomez

17:45 - 18:30 Oral Presentation

17:45 - 17:55 - A 16 Breastfeeding and risk of Postpartum Relapses in women with Multiple Sclerosis

Authors: Nora Fernández Liguori; Berenice Silva; Diana Klajn;Fernando Cáceres;María Laura Saladino;Orlando Garcea.

17:55 - 18:05 - A 50 Epidemiology of Multiple Sclerosis in The Island of Margarita, Venezuela

Authors: Arnoldo Soto; Enrique Ordaz;Evelyn Bracho;Marisol Gallardo;Simon Gomez.

18:05 - 18:15 - A 51 Epstein-Barr Virus and Smoking Habits in Brazilian patients with Multiple Sclerosis

Authors: Cátia Silva;Celso Luis Silva Oliveira; Fabio Siquineli;Francisco Tomaz Menezes Oliveira;Heloisa Helena

Ruocco;Joseph Bruno Bidin Brooks;Marcus Vinicius Magno Gonçalves; Sidney Gomes;Sonia Beatriz Felix

Ribeiro;Yara Dadalti Fragoso.

18:15- 18:25 - A 52 Epstein-Barr Vírus Infection of the Central Nervous System and Multiple Sclerosis

Disease Activity

Authors: Carlos Otávio Brandão;Adriel dos Santos Moraes;Alessandro S Farias;Alfredo Damasceno;Analeda F

Longhini;Benito Pereira Damasceno;Denise Sayuri Tukada;Felipe Von Glehn; Juan Cabanillas; Leonardo de Deus

Silva;Leonilda M B Santos.

16:30 - 18:30 | Round Table - Genetic and Familiar MS and MNO in Latin AmericaRooM seGÓVia iiiChair: Damácio Ramon Kaimen Maciel

Secretary: Eduardo Paradella

16:30 - 16:50 - Genetics Studies in Latinamerica

Speaker 1: Teresa Corona

16:50 - 17:10 - Genetics aspects of MS in Brazil

Speaker 2: Soniza Vieira Alves Leon

17:10 - 17:30 - Ancestry information markers application to studies of neurological autoimmune

diseases in admixed population

Speaker 4: - Doralina Guimarães Brum Souza

17:30 - 17:50 Familial MS

Speaker 5: Carmen Antão Paiva

17:50 - 18:10 - Genetics in Colombia

Speaker 6: Jaime Toro

18:10 - 18:30 - Discusion

18:30 - 20:30 | TEVA SymposiumSharpening the Management of MSRooM seGÓVias18:30 - 18:40 - Welcome and Introduction

Presenter: Soniza Vieira Alves Leon

18:40 - 19:00 - Importance of Non Biologic Complex Drugs in MS Treatment

Speaker: Jill Conners

19:00 - 19:30 - Widening the Glatiramer Acetate Data: The GALA Study

Speaker: Robert Zivadinov

19:30 - 19:55 - MS Therapy: Addressing the CNS Pathology

Speaker: Denisa Hurtukova

19:55 - 20:00 - Discussion

Discussant: Soniza Vieira Alves Leon

November 29th

08:00 - 09:00 | Plenary Session - Jean Martin Charcot Section

Cellebration of Charcot Birthday in November-29 - ANERJ

RooM seGÓVias

Chair: Jose Mauro Braz de Lima

Speaker: Helcio Alvarenga

Secretary: Maria Clinete Sampaio Lacativa

09:00 - 10:00 | Plenary Session - What is Ms And What is Not Ms

RooM seGÓVias

Chair: Charles PeterTilbery

Secretary: Rodrigo Barbosa Thomaz

09:00 - 09:30 - When one bout and one MRI is MS

Speaker 1: Jorge Barahona

09:30 - 10:00 - When one bout and one MRI is not MS

Speaker 2: Soniza Vieira Alves Leon

10:00 - 10:30 | Coffee Break

RooM seGÓVias

10:30 - 12:00 | Plenary Session - MS in Americas

MS in Latin America and Canada

RooM seGÓVias

Chair: Teresa Corona

Secretary: Doralina Guimarães Brum Souza

10:30 - 10:40 - Natural History MS in Spanish countries

Speaker 1: Liliana Patrucco

10:40 - 11:00 - Natural History MS in Brazil

Speaker 2: Cláudia Cristina Ferreira Vasconcelos

11:00 - 11:20 - Natural History of Pediatric MS in Latin America

Speaker 3: Silvia Tenembaum

11:20 - 12:00 - Natural History MS in Canada

Speaker 4: Marcelo Kremenchutzky

12:30 - 14:00 | Biogen Idec Symposium : Commitment to Treatments of Demyelinating

and Neurodegenerative Diseases

RooM seGÓVias

12:30 - 12:40 - Opening remarks

Chair: Regina Papais Alvarenga

12:40 - 13:15 - Tailoring Therapy for the MS Patient: Challenges in Choosing Right Treatment Options

Speaker: Hans-Peter Hartung

32 33

13:15 - 13:50 - Biogen Idec Neurology: Current Status of Clinical Development

Speaker: Rick Munschauer

13:50 - 14:00 - Closing remarks and Q&A

Moderator: Regina Papais Alvarenga

14:00 - 16:00 | Round Table - Idiopathic Inflammatory Demyelinating Diseases (IIDD)

in Latin America

RooM oRieNte

Chair: Cláudia Cristina Ferreira Vasconcelos

Secretary: Mônica Koncke Fiuza Parolin

14:00 - 14:20 - IIDD in Rio Grande do Sul

Speaker: Maria Cecília de Vecino

14:20 - 14:40 - IIDD in Santa Catarina

Speaker: Suzana Costa Nunes Machado

14:40 - 15:00 - IIDD in Paraná

Speaker: Mônica Koncke Fiuza Parolin

14:40 - 15:00 - IIDD in Paraná

Speaker: Walter Oleschko Arruda

15:00 - 15:20 - IIDD in São Paulo

Speaker: Alfredo Damasceno

15:00 - 15:20 - IIDD in São Paulo

Speaker: Luiz Domingos Mendes Melges

15:20 - 15:40 - IIDD in São Paulo

Speaker: Yara Dadalti Fragoso / Maria Sheila Rocha

15:40 - 16:00 - IIDD in Rio de Janeiro

Speaker: Elizabeth Batista, Ana Beatriz Calmon e Maria Lucia Pimentel

14:00 - 16:00 | Round Table - Pit Falls in MS Diagnosis

RooM seGÓVia i

Chair: Sebastião Eurico

Secretary: Claudia Rego

14:00 - 14:20 - Eritematosous Systemic Lupus Versus MS

Speaker 1: Denise Sisterolli Diniz

14:20 - 14:40 - Lyme Disease Versus MS

Speaker 2: Maria Lúcia Vellutini Pimentel

14:40 - 15:00 - Myastenia Gravis and IIDD

Speaker 3: Elza Dias Tosta da Silva

15:00 - 15:20 - Behcet Disease vs MS

Speaker 4: Ernani Maciel

15:20 - 15:40 - HAM-TSP Versus Primary Progressive MS

Speaker 5: Abelardo de Queiroz C. Araújo

15:40 - 16:00 - Hereditary Ataxia vs MS

Speaker 6: Helio Teive

14:00 - 16:00 | Course - Update - Multiple Sclerosis For All

RooM seGÓVia ii

Chair: Luiz Domingos Mendes Melges

Secretary: Letícia Fezer

14:00 - 14:20 - The concept and classification of demyelinating diseases

Speaker: 1: Fabiola Rachid

14:20 - 14:40 - Clinical isolated syndrome

Speaker 2: Roberto Rotta Escalante

14:40 - 15:00 - Multiple Sclerosis Diagnostic Criteria

Speaker 3: Liliana Patrucco

15:00 - 15:20 - MRI for MS Diagnosis

Speaker 4: Emerson Gasparetto

15:20 - 15:40 - Inflammation and degeneration in MS

Speaker 5: Douglas Goodin

15:40 - 16:00 - Treatments Algoritms In MS

Speaker 6: Carlos Cuevas

14:00 - 16:00 | Round Table

Fatigue: a MS “Phantom” Symptom

RooM seGÓVia iii

Chair:Maria Fernanda Mendes

Secretary: Debora Sales

14:00 - 14:20 - Fatigue and MS: An Overview

Speaker 1: Regina Papais Alvarenga

14:20 - 14:40 - Fatigue and MRI

Speaker 2: Fernanda Moll / Fernanda Erthal

14:40 - 15:00 - Fatigue and disability

Speaker 3: Helcio Alvarenga Filho

15:00 - 15:20 - Cognition and Mental Fatigue

Speaker 4: Maria Fernanda Mendes

15:20 - 15:40 - Physical Intervention, Fatigue and Immunology

Speaker 5: Cleonice Bento

15:40 - 16:00 - Fatigue Treatment

Speaker 6: Damácio Ramon Kaimen Maciel

16:00 - 16:30 - Coffee Break

16:30-18:30 | Round Table - Idiopathic Inflammatory Demyelinating Diseases (IIDD) in

Latin America

RooM oRieNte

Chair: Solange Camargo

Secretary:Heloise Helene Siqueira

34 35

16:30 - 16:50 - IIDD in Pernambuco

Speaker 1: Maria Lúcia Brito Ferreira

16:50 - 17:10 - IIDD in Mato Grosso

Speaker 2: Anderson Kuntz Grzesiuk

16:50 - 17:10 - IIDD in Mato Grosso

Speaker 2: Heloise Helena de Figueiredo Siqueira

17:10 - 17:30 - IIDD in Goiás

Speaker 3: Denise Sisterolli Diniz

17:30 - 17:50 - IIDD in Brasília

Speaker 4: Patricia Beatriz Christino Marinho

17:50 - 18:10 - IIDD in Minas Gerais

Speaker 5: Antonio Gomes Neto

16:30-18:30 | Round Table - Challenges in MS: Diagnosis and Therapeutic Decisions

RooM seGÓVia i

Chair: Soniza Vieira Alves Leon

16:30 - 17:10 Differential Diagnosis PML in the Setting of MS

Speaker 1: Nancy Richert

17:10 - 17:30 The Management of Clinical Isolated Syndrome With High Risk to MS Conversion

Speaker 2: Darwin Vizcarra

17:30 - 17:50 The Management of Secondary Progressive MS With Active Lesions In MRI

Speaker 3: Vladmiro Sinay

17:50 - 18:10 The Management of “Benign” MS

Speaker 4: Elizabeth Armas

18:10 - 18:30 The Management of “Severe” MS?

Speaker 5: Gutemberg Augusto Cruz dos Santos

16:30-18:30 | Round Table - Update in Methods of Investigation in Multiple Sclerosis

RooM seGÓVia ii

Chair: Mauricio Klajenberg.

Secretary: Adriano Miranda

16:30 - 17:00 - The role of advanced MRI techniques in the MS Diagnosis Criteria for Multiple Sclerosis

Speaker 1: Emerson Gasparetto

17:00 - 17:30 - Spinal Cord MRI

Speaker 2: Fernanda Rueda Lopes

17:30 - 18:00 - Electrophysiological Methods

Speaker 3: Joseph Brooks

18:00 - 18:30 - Cerebral Spinal Fluid In MS

Speaker 4: Carlos Oehninger

16:30-18:30 | Round Table - President and Delegates of Latin American Committee of

Research and Treatment in Cognition and Multiple Sclerosis

RooM seGÓVia iii

Secretary: Thais Conceição Monteiro

Chair: Benito Damasceno

16:30 - 16:50 - Cognition and MS - Overview

Speaker 1: Miguel Angel Macias

16:50 - 17:10 - MS Cognition Studies in Spanish Speaking Latin American Countries

Speaker 2: Fernando Caceres

17:10 - 17:30 - Cognitive Different Pattern In MS According Clinical Types

Speaker 3: Renata Paes

17:30 - 17:50 - Topics on MS and cognition - Experience in Colombia

Speaker 4: Juan Garcia Bonitto

17:50 - 18:10 - Personality and MS

Speaker 5: Edgardo Reich

18:10 - 18:30 - Cognition and MRI In MS

Speaker 6: Alfredo Damasceno

18:30 - 20:00 | Merck Symposium

RooM seGÓVias

18:30 - 18:40 - Opening

Speaker: Soniza Vieira Alves Leon

18:40 - 19:10 - Optimising Multiple Sclerosis Therapy

Speaker: Oscar fernandez

19:10 - 19:40 - “Multiple Sclerosis - Children’s approach”

Speaker: Silvia Tenembaum

36 37

November 30th

08:00 - 10:00 | Plenary Session

RooM seGÓVias

Chair: Jose A Cabrera Gomez

Secretary: Maria Sheila Rocha

08:00 - 08:30 - Neuromyelits Optica with recurrent clinical course - A new demyelinating syndrome

Speaker 1: Raul Mandler

08:30 - 09:00 - The relative frequency of NMO and Multiple Sclerosis in Latin American

Speaker 2: Regina Papais Alvarenga

09:00 - 10:00 - Demyelinating diseases in Asian population

Speaker 3: Jun-Ichi Kira

10:00 - 10:30 | Coffee Break

RooM seGÓVias

10:30 - 12:00 | Plenary Section - Neuromyelits Optica in Latin America

RooM seGÓVias

Chair: Alberto Alan Gabbay

Secretary: Elizabeth Regina Comini Frota

10:30 - 11:00 - NMO - Genetic and Epidemiology in Cuba and Martinique

Speaker 1: Jose A Cabrera Gomez

11:00 - 11:30 - NMO and Potencial Evoked Visual Test

Speaker 3: Silvio Pessanha Neto

11:30 - 12:00 - MRI pattern in NMO

Speaker 4: Emerson Gasparetto

12:30 - 14:00 | Bayer Symposium - Impact of MS on Survival and the Role of Interferon 1-B

RooM seGÓVias

12:30 - 12:40 - Introduction

Speaker: Marcos Papais Alvarenga

12:40 - 13:10 - Impact of MS on Survival

Speaker:Marcos Papais Alvarenga

13:10 - 13:50 - Interferon β 1-b and Survival

Speaker:Douglas Goodin

13:50 - 13:55 - Q&A

13:55 - 14:00 - Close

14:00 - 16:00 | Round Table - Clinical Trials and Guidelines MS treatment in Latin AmericanRooM oRieNte

Chair: Jorge Nogales-Gaete

Secretary: Valéria Coelho Santa Rita Pereira

14:00 - 14:20 - Brazilian Recommendation for MS treatment: Medical societies X Government

Speaker 1: Elza Dias Tosta da Silva

14:20 - 14:40 - MS Guidelines Treatment in Brazil

Speaker 2: Suzana Costa Nunes Machado

14:40 - 15:00 - MS Guidelines in Latin America

Speaker 3: Adriana Carra

15:00 - 15:20 - MS Guidelines from LACTRIMS

Speaker 4: Patricio Abad

15:20 - 15:40 - Addressing Natalizumab Therapy related Risks (Globally and Locally)

Speaker 6: John Richert

15:40 - 16:00 - Discussion

14:00 - 16:00 | Session - Hot TopicsRooM seGÓVia i

Chair: Antonio Gomes Neto

Secretary: Paulo Christo

14:00 - 14:20 - Chronic cerebro-spinal venous insufficiency

Speaker 1: Leonardo de Deus Silva

14:20 - 14:40 - Biological markers in MS - how long we are?

Speaker 2: Elizabeth Regina Comini Frota

14:40 - 15:00 - Identification of responders and non-responders to immunomoulators

Speaker 3: Valéria Coelho Santa Rita Pereira

15:00 - 15:15 - A 74 Inter- And Intragenerational Study Of Ms Familial Cases In A Reference Center In

The City Of Rio De Janeiro.

Authors: Melina da Silva Bernardes;Carmem Lucia Antão Paiva;Cláudia Vasconcelos;Elizabeth Batista;Fernanda

Ferreira Chaves da Costa Pereira; Marcos Papais Alvarenga;Regina Maria Papais Alvarenga;Solange Camargo.

15:15 - 15:30 - A 81 Molecular targets involved in Pathogenesis and Response to Therapy of

Demyelinating Diseases

Authors: Majel Cervantes-Llanos;Carmen Valenzuela-Silva;Giselle Pentón-Rol; Gregorio Martínez-Sánchez;Ileana

Lopategui-Cabezas;José Cabrera-Gómez; Pedro López-Saura;Ruby Alonso-Ramírez.

15:30 - 15:45 - A 124 Research of Locus Xq22.3 as transcription source for Endogenous Retrovirus and

its association with the Multiple Sclerosis Etiology

Authors: Guilherme Sciascia do Olival;Camila Malta Romano;Charles Peter Tilbery; Laura Sumita;Luis S Nali;Maria

Cristina Domingues Fink;Rodrigo Barbosa Thomaz; Tiago S Faria;Vitor B Cavenaghi;Vitor Serafim.

15:45 - 16:00 - A 41 Disease modifying therapy withdrawal in relapsing-remitting multiple sclerosis:

follow-up of 40 patients.

Authors: Guilherme Sciascia do Olival; Vitor Breseghello Cavenaghi; Vitor Serafim; Rodrigo Barbosa Thomaz;

Charles Peter Tilbery

38 39

14:00 - 16:00 | Course - Neuroimmunology of Idiopathic Inflammatory Demyelinating DiseasesRooM seGÓVia ii

Secretary: Ulisses Cerqueira Linhares

14:00 - 14:10 - Neuroimmunology up to date

Chair: Andres Villa

14:10 - 14:40 - Immunological and pathological features of neuromyelitis optica

Speaker 1: Jun-Ichi Kira

14:40 - 15:10 - Neuroimmunology of MS

Speaker 2: Jorge Correale

15:10 - 15:35 - Experimental Allergic Encephalitis

Speaker 3: Alessandro Faria

15:35 - 16:00 - The TH17 cell biology in multiple sclerosis and neuromyelitis optica

Speaker 4: Cleonice Bento

14:00-16:00 | Round Table - Advances in Symptomatic TreatmentRooM seGÓVia iii

Chair: Orlando Garcea

Secretary: Camila Rodrigues

14:00 - 14:20 - The Neuro rehabilitation is part of symptomatic treatment

Speaker: Fernando Caceres

14:20 - 14:40 - Bladder and sphincter dysfunction

Speaker: Camila Rodrigues

14:40 - 15:00 - Spasticity

Speaker: Elizabeth Armas

15:00 - 15:20 - Sexual Disfunction

Speaker: Fernando Hammuy Díaz de Bedoya

15:20 - 15:40 - Ataxia and trembling

Speaker: Orlando Garcea

15:40 - 16:00 - Debate

16:30 - 18:00 | Activities - President and Delegates of Latin American Committee of Research and Treatment in Multiple SclerosisRooM oRieNte

Coordinator: Jorge Nogales-Gaete

Secretary: Violeta Diaz

16:30 - 16:50 - LACTRIMS - Who are we?

Speaker: Jorge Nogales-Gaete

16:50 - 17:10 - Groups in Latin American with specific targets: How does it / can it really work?

Speaker: Miguel Córdova Ruiz

17:10 - 17:30 - A new LACTRIMS

Speaker: Miguel Angel Macias

16:30 - 18:30 h | AWARDSHelcio Alvarenga AwardsRooM seGÓVia i

Chair: Helcio Alvarenga

Secretary: Heloise Helena de Figueiredo Siqueira

16:30 - 18:30 | Round Table - Research in IIDD Latin American Syndromes of NMO

spectrum

RooM seGÓVia ii

Chair: Jun-Ichi Kira

Secretary: Marina Papais Alvarenga

16:30 - 16:50 - Caracteristicas da Neurite Optica nas Síndromes do Complexo NMO

Speaker 1: Elizabeth Batista

16:50 - 17:10 - Brainstein syndrome and encephaloty in NMO

Speaker 2: Marcos Papais Alvarenga

17:10 - 17:30 - Positivity frequency of Anti Aqp4 with the Elisa Method in NMO patients treated at the

Sarah Network – Brasilia Unity

Speaker 4: Maria Cristina Del Negro Barroso Freitas

17:30 - 17:50 - Positivity frequency of Anti aqp4 with the Indirect Immunofluorescence Method in

Patients With Nmo in São Paulo

Speaker 3: Tarso Adoni

17:50 - 18:10 - A 54 Resting-State Functional Magnetic Resonance Imaging in the assessment of

patients with Neuromyelitis Optica

Authors: Emerson Leandro Gasparetto; Fabiola Malfetano; Fernanda Cristina Rueda Lopes; Fernanda Miraldi;

Isabela Meira; Paulo Roberto Valle Bahia; Romeu Domingues; Soniza Alves-Leon.

18:10 - 18:30 - Transverse Myelitis Post Dengue Infection

Speaker 4: Adriano Miranda

16:30 - 18:00 | LACTRIMS Oral Presentation MS

RooM seGÓVia iii

Chair: Victor Rivera

Secretary: Fabíola Rachid Malfetano

16:30 - 16:40 - A 3 Acute Disseminated Encephalomyelitis: Presentation in the adult population.

Authors: Guilherme Sciascia do Olival;Camila Malta Romano;Charles Peter Tilbery;Laura Sumita;Luis S Nali;Maria

Cristina Domingues Fink;Rodrigo Barbosa Thomaz; Tiago S Faria; Vitor B Cavenaghi;Vitor Serafim.

16:40 - 16:50 - A 6 Aplication of the Mcdonald 2010 criteria for the diagnosis of Multiple Sclerosis in

an argentinean cohort of patients with clinically isolated syndromes

Authors: Liiana Patrucco;Edgardo Cristiano;Juan Ignacio Rojas.

16:50 - 17:00 - A 21 Clinical analysis of Malignant MS in a brazilian reference center for MS

Authors:Fabrício da Costa Hampshire de Araújo;Cláudia Cristina Ferreira Vasconcelos ;Gutemberg Augusto

Cruz dos Santos;Juliana Calvet Kallenbach Aurenção;Regina Maria Papais Alvarenga;Solange Maria das Graças

Gomes Camargo.

17:00 - 17:10 - A 42 Prognostic factors of Malignant Multiple Scleosis in a cohort of argentinean patients

Authors: Liliana Patrucco;Edgardo Cristiano;Jimena Miguez;Juan Ignacio Rojas;Verónica Fleitas.

17:10 - 17:20 - A 92 Multiple Sclerosis: natural history and prognostic factors in brazilian patients.

Authors: Gutemberg Augusto Cruz dos Santos;Claudia Cristina Ferreira Vasconcelos;Fabrício Hampshire

Araujo;Juliana Calvet Kallembach;Luiz Claudio Santos Thuler;Regina Maria Papais Alvarenga;Solange Maria das

Graças Gomes Camargo.

40 41

17:20 - 17:30 - A 112 Prevalence of Pseudotumoral Demyelinating Lesions in an oncology reference center

Authors: Yasmine Coura Torres; Marco Antônio Sales Dantas Lima; Soniza Vieira Alves Leon.

17:30 - 17:40 - A 11 Brain atrophy as a non response predictor to Interferon? In Relapsing Remitting

Multiple Sclerosis

Authors: Juan Ignacio Rojas;Edgardo Cristiano;Liliana Patucco.

17:40 - 17:50 - A 12 Brain Atrophy evaluation in Multiple Sclerosis Patients: A comparison study with

clinically isolated syndrome and Neuromyelitis Optica

Authors: Fernanda Miraldi Clemente Pessôa;Emerson Leandro Gasparetto;Fernanda Cristina Rueda Lopes;Soniza

Vieira Alves-Leon.

17:40 - 17:50 - A 35 Cytokine profile in Relapsing-Remitting Multiple Sclerosis patients and the

association with the progression and the activity of the disease

Authors: Ana Paula Kallaur;Andréa Name Colado Simão;Damácio Ramon Kaimen-Maciel;Edna Maria Vissoci

Reiche;Elaine Regina Delicato de Almeida;Helena Kaminami Morimoto;Josiane Lopes;Larissa Muliterno

Pelegrino;Renato Marques Andrade;Sayonara Rangel Oliveira;Wildea Lice de Carvalho Jennings Pereira.

18:30-19:30 | Clousure - Hold of the New Lactrims Directors Board and Prize Giving

Ceremony

RooM seGÓVia i

Prizes will be given to the following categories

1. Best Latin American published papers between 2010 and 2012

2. Best posters presented in 7th LACTRIMS-RIO

3. Best posters presented for young researchers in 7th LACTRIMS - RIO

4.Best posters presented in 5th Congress of ANERJ

5. Best works submitted by students in LACTRIMS/ANERJ - HELCIO ALVARENGA AWARD

ANERJ SCIENTIFIC PROGRAM

42 43

12:30 - 13:30 | V Anerj Congress - Symposium

Video-conference: Involuntary Movements: clinic and botulinum toxin treatment

with ENMG

RooM seGÓVia iV

Moderator: Denise Nicaretta

Speakers: Ana Lucia Rosso, Flavio Henrique de Rezende Costa

14:00 - 16:00 | Round Table - V Anerj Congress - Epilepsy thoughout lifeRooM seGÓVia iV

Secretaty: Yara Ganeo

Moderator: Cristiane Marins

14:00 - 14:40 - Neonatal and breastfeeding

Speaker: Lucia Fontenelle

14:40 - 15:20 - Kindergarten and Grammar School

Speaker: Gustavo Adolfo Rodrigues Valle

15:20 - 16:00 - Teenager and Adult

Speaker: Cristiane Afonso

16:00 - 16:30 | Coffee Break

16:30 - 17:30 | Round Table - V Anerj Congress - Rehabilitation and NeurophysiologyRooM seGÓVia iV

Secretaty: Fernanda Guimarães

Moderator: José Vicente Martins

16:30 - 16:50 - Miofascial pain

Speaker: Palmiro Torrieri Júnior

16:50 - 17:10 - Chronic Lumbar pain

Speaker: Verônica Brandão

17:10 - 17:30 - Neuropathic pain

Speaker: Artur Padão Gosling

17:30 - 18:30 | Round Table - V Anerj - NeuroinfectionRooM seGÓVia iV

Secretary: Ricardo Canuto

Moderator: Marzia P. Sohler

17:30 - 18:00 - Neurological manifestations of encephalitis

Speaker: Marcus Tulius T. Silva

18:00 - 18:30 - Neuroimage in encephalitis

Speaker: Isabella Guedes

18:30 - 19:30 | Opening Symposium - V Anerj Congress - Alcoholism Perspective in Public Health

RooM seGÓVia iV

Speaker: Jose Mauro Braz de Lima

November 28th

08:00 - 09:00 | Plenary Session - V Anerj Congress – Lactrims PlenaryRooM seGÓVias

Chair: Jorge Nogales-Gaete

08:10 - 08:30 - Opening

Speaker 1: Victor Rivera

08:30 - 09:00 - The impact of the published papers: What do they say about Demyelination Inflammatory

Idiopathic Diseases in Latin America?

Speaker 2: Regina Papais Alvarenga

09:00 - 10:00 | Round Table - V Anerj Congress - Movement DisordersRooM seGÓVia iV

Secretary: Celmir de Oliveira Vilaça

Moderator: Luiz Felipe Vasconcellos

09:00 - 09:20 - Cognitive alterations in Parkinson’s Disease

Speaker: Raphael Breder

09:20 - 09:40 - Sleep disfunctions in Parkinson’s Disease

Speaker:João Santos Pereira

09:40 - 10:00 - Coréias: Differential diagnostic

Speaker: Mariana Spitz

10:00-10:30 | Coffee Break

10:30 - 11:10 | Round Table - V Anerj Congress - Movement DisordersRooM seGÓVia iV

10:30 - 10:50 - Tiques - Up to date

Speaker: Marco Antonio Araújo Leite

10:50 - 11:10 - Demyelinating Diseases and Movement disfunctions

Speaker: Osvaldo JM Nascimento

11:10 - 12:30 | Round Table - V Anerj Congress - Cognition

RooM seGÓVia iV

Secretary: Denise Nicaretta

Moderator: Tamara Checcacci

11:10 - 11:30 - Alzheimer 2011

Speaker: Ana Cristina Cabral de Lima

11:30 - 11:50 - Dementia with Lewy bodies

Speaker: Luiz Felipe Vasconcellos

11:50 - 12:10 - Mixed Dementia

Speaker: Eliasz Engelhardt

12:10 - 12:30 - Cognitive vascular impairment in sickle cell disease

Speaker: Ana Claudia C. Leite

44 45

14:00 - 14:20 - Genetic contribution in ELA

Speaker: Pedro Cabello

14:20 - 14:40 - Epidemiologic aspects of ELA in Latin America

Speaker: Carlos Ketzoian

14:40 - 15:00 - Epidemiologic aspects of ELA in Brazil / Rio de Janeiro

Speaker: Marli Pernes

15:00 - 15:20 - Conventional Magnetic resonance and advanced image in the diagnosis of ELA. What

are the main data?

Speaker: Isabella Guedes

15:20 - 15:40 - ELA - Syndrome or disease – The Nosological limits

Speaker: Jose Mauro Braz de Lima

15:40 - 16:00 - Debate

16:00 - 16:30 | Coffee Break

16:30 - 18:00 | Conference - V Anerj Congress - NeuroimmunologyHow many MS patients are there in the State of Rio de Janeiro?RooM seGÓVia iV

Secretary: Marina Alvarenga

Moderator: Cláudia Cristina Ferreira Vasconcelos

16:30 - 16:40 - Prevalence study on MS in the city of Rio de Janeiro

Speaker: Maria Clinete Sampaio Lacativa

16:40 - 16:50 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Federal

da Lagoa

Speaker: Marcos Papais Alvarenga

16:50 - 17:00 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Federal

dos Servidores do Estado

Speaker: Marcelo Cagy

17:00 - 17:10 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Clementino

Fraga Filho

Speaker: Fabiola Rachid

17:10 - 17:20 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Santa Casa de

Misericórdia

Speaker: Leticia Fezer

17:20 - 17:30 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Pedro

Ernesto

Speaker: José Maurício Godoy

17:30 - 17:40 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Ordem Terceira

da Penitência

Speaker: Fernando Figueira

17:40 - 17:50 - MS Prevalence study in the Sul Fluminense Region

Speaker: Ana Beatriz Calmon Nogueira da Gama

17:50 - 18:00 - Data on MS prevalence studies in patients in the city of Volta Redonda

Speaker: Fernanda Pereira

18:00 - 19:00 | General Assembly Anerj

November 29th

08:00 - 09:00 | Plenary Session - Jean Martin Charcot Section

Cellebration of Charcot Birthday in November-29 - ANERJRooM seGÓVias

Chair: Regina Papais Alvarenga

Speaker: Helcio Alvarenga, Jose Mauro Braz de Lima

09:00 - 10:00 | Round Table - V Anerj Congress - Peripheral Neuropathy and pain - Neuropathies of fine fibers / Neuropathic painRooM seGÓVia iV

Secretary: João Gabriel Dib Farinhas

Moderator: Giseli Quintanilha

09:00 - 09:20 - Pain: Central and peripheral sensitivity – the role of the glial cell

Speaker: André Matta

09:20 - 09:40 - Electroneuromyography in pain?

Speaker:Eduardo Davidovich

09:40 - 10:00 - Automatic evaluation

Speaker: Bruno Coutinho

10:00 - 10:30 | Coffee Break

10:30 - 11:10 | Round Table - V Anerj Congress - Peripheral Neuropathy and Pain – Part 2RooM seGÓVia iV

10:30 - 10:50 - Painful peripheral Neuropathies

Speaker: Camila Pupe

10:50 - 11:10 - New evaluation instruments for fine fiber neuropathies

Speaker: Osvaldo JM Nascimento, Bruno Coutinho

11:10 - 12:40 | Round Table - V Anerj Congress - NeuropediatricsRooM seGÓVia iV

Secretary: Carla Quero

Moderator: Tania Regina D. Saad Salles

11:10 - 11:40 - Perinatal inflammation: Implications for Neurological and Neuropsychiatric diseases in childhood

Speaker:Adailton Pontes

11:40 - 12:10 - Asperger Syndrome X Autistic Specter

Speaker: Rossano Cabral de Lima

12:10 - 12:40 - Learning disorders – It is not always ADHD

Speaker: Solange Vianna Dultra

14:00 - 16:00 | Round Table - V Anerj Congress - Motor NeuroneRooM seGÓVia iV

Secretary: Claudio Heitor Gress

Moderator: Carlos Henrique Melo Reis

46 47

RooM seGÓVia iVNovember 30th

08:00 - 09:00 | PLENARY SESSION - V Anerj Congress - Lactrims Plenary

RooM seGÓVias

Chair: Jose A Cabrera Gomez

Secretary: Maria Sheila Rocha

08:00 - 08:30 - Neuromyelits Optica with recurrent clinical course - A new demyelinating syndrome

Speaker:Raul Mandler

08:30 - 09:00 - Multiple Sclerosis and Neuromyelitis Optica in Caribbean Population

Speaker: José A. Cabrera Gomez

09:00 - 10:00 | Round Table - V Anerj Congress - HeadacheRooM seGÓVia iV

Secretary: Greice Cardoso de Carvalho Silva

Moderator: Eliana Maranhão

09:00 - 09:20 - Migraine aura

Speaker: Maurice Vincent

09:20 - 09:40 - Migraine and cerebellum

Speaker: Cristiana Goes

09:40 - 10:00 - Migraine and vertigo

Speaker: Péricles Maranhão-Filho

10:00 - 10:30 | Coffee Break

10:30 - 10:50 | Round Table - V Anerj Congress - Headache - Part 2RooM seGÓVia iV

10:30 - 10:50 - Migraine and SAF

Speaker: Norma Fleming

10:50 - 12:30 | Round Table - V Congresso da ANERJ - History of MedicineRooM seGÓVia iV

Secretary: Cristiana Goes

Moderator: Maria Clinete Sampaio Lacativa

10:50 - 11:20 - Art in Neurology

Speaker:

10:50 - 11:00 - In Litterature

Speaker: Maria Clinete Sampaio Lacativa

11:00 - 11:10 - In Music

Speaker: Antonio Luiz Werneck

11:10 - 11:20 - In painting and sculpture

Speaker: Péricles Maranhão-Filho

11:20 - 11:50 - Charles David Marsden and the functional anatomy of the base lymph nodes

Speaker: Antonio Luiz Werneck

11:50 - 12:20 - The common origin of teaching practice of mental and neurological diseases in Brazil

Speaker: Marleide Gomes

12:20 - 12:50 - Who’s Who?

Speaker: Péricles Maranhão-Filho

12:50 - 13:50 | imposium Biogen IDEC - Progressive Multifocal

Leucoencephalopathy in MS patients

RooM seGÓVia iV

Chair: Marcelo Cagy

Speaker: Gabriel Paiva da Silva Lima

14:00 - 16:00 | Round Table - V Anerj - Cerebrovascular DiseasesSevere Phase Ischemic CvaRooM seGÓVia iV

Secretary: Eduardo Prezzi

Moderator: Marco Oliveira Py

14:00 - 14:45 - Debate: Trombolisis beyond 4,5 hours (pros and cons)

Speaker: Henry Pereira da Silva

14:00 - 14:45 - Debate: Trombolisis beyond 4,5 hours (pros and cons)

Speaker: Soraya Pulier

14:45 - 15:30 - Debate: Decompressive craniectomy beyond 60 years (pros and cons)

Speaker: Christian Naurath

14:45 - 15:30 - Debate: Decompressive craniectomy beyond 60 years (pros and cons)

Speaker: Daniel Paes de Almeida dos Santos

15:30 - 16:00 - Diffusion allied to perfusion in severe ischemia

Speaker: Cristiana Caires

16:00 - 16:30 | Coffee Break

16:30 - 18:00 | Round Table - V Anerj Congress - Neurointensive TreatmentRooM seGÓVia iV

Secretary:Daniel Amitrano

Moderator: Bruno Castelo Branco

16:30 - 16:50 - Vasospasm in HSA – New techniques and treatment

Speaker: Bernardo Liberato

16:50 - 17:10 - The role of the EEG in the Neurointensive care unit

Speaker: Maria Lucia Mendonça

17:10 - 17:30 - Hypothermia. When and what to do?

Speaker: Ricardo Turon

17:30 - 17:50 - Cranioencephalic Trauma

Speaker: Fernando Mendonça

17:50 - 18:00 - Debate

18:00-19:00 | CLOSURE

V Anerj Congress - Closure

RooM seGÓVia iV

48 49

AUTHORS ABSTRACTS

abib, c. a 25

adoni, t. a 83

agostinho, l. a 9; a 10

aguero, F. a 83

albuquerque, l. a 137; a 152

alcántara, J. a 158

ale-Martínez, M. a 95

alfieri, d. a 148

almeida, e. a 148; a 35

almeida, s. a 36; a 40; a 58; a 83

alonso, R. a 3

alonso-Ramírez, R. a 81

alvarenga Filho, h. a 86; a 107; a 130; a 32

alvarenga, h. a 140; a 37;a 72;a 140; a 1;a 38;a 89; a 97;a 49;a 65; a 74; a 171

alvarenga, M. a 1; a 97; a 38

alvarenga, R. a 72; a 139; a 140; a 37; a 86; a 32; a 26; a 109; a 103; a 106; a 111; a 113; a 114; a 133; a 136; a 151; a 66; a 89; a 90; a 97; a 21; a 29; a 30; a 49; a 57; a 65; a 66; a 74; a 88; a 92; a 107; a 1; a 38; a 171; P 1; P 15;

alves, l. a 25

alves-leon, s. a 144; a 54; a 55; a 112; a 10; a 58; a 88 ; a 96; a 134; a 138; a 36; a 40; a 12; a 83; a 9; a 164; P 9; a 171

andrade, h. a 153

andrade, P. a 19

andrade, R. a 148; a 35; a 104; a 115; a 84

andres Villa a 99

apostolos, s. a 101

araújo, F. a 21; a 92; a 30

araújo, N. a 30

arbildi, M. a 158

arelis, a. a 110; a 163; a 27

arias, e. a 125

armas, e. a 127; a 146

arnold, d. a 46

arruda, W. a 137; a 138; a 83

arzuaga, a. a 76

aurenção, J. a 21

Ávalos, J. a 7

aviña, G. a 45

azevedo, l. a 117; a 56; a 70

Bahia, P. a 132; a 4; a 54

Banwell, B. a 129

Baptista, s. a 36; a 40; a 58; a 83; a 96

Barahona, J. P 8

Baranauskas, V. a 165

Baranzini, s. P 4

Barbosa, a. a 56

Barkhof, F. a 161; a 44

Bar-or, a. a 161; a 24; a 46; a 59

Barreira, a. a 155; a 170

Bastos, a. a 117; a 70

Batista, e. a 140; a 37; a 26; a 38; a 89; a 74

Becker, J. a 137

Beckmann, K. a 131

Benedict, R. a 85

INDEX AUTHORS Benítez-Fuentes, J. a 95

Bento, c. a 169; a 97

Bermudez, J. a 101; a 33

Bernardes, M. a 38; a 74

Besada, c. a 14; a 61 Boyko, a. a 129

Bracho, e. a 50

Brandão, c. a 89; a 52

Brito, c. a 49

Brooks, J. a 126;a 138;a 2;a 51;a 83; a 137

Brucki, s. a 153;a 20

Brum, d. a 155

Buzó, R. a 158

cabanillas, J. a 52

cabral, F. a 144

caceres, F. a 85

cáceres, F. a 16;a 48

cal, h. a 31 calabresi, P. a 161

callegaro, d. a 160;a 101;a 128;a 33

calvet, J. a 37

calzadilla, l. a 91

camacho-Rodríguez, h a 95

camargo, s. a 140;a 37;a 89;a 49;a 74; a 136;a 21;a 30;a 92;a 38

camilo, d. a 165

campanella, l. a 140; a 65

carneiro, M. a 156 carolino,F. a 72

carrá, a. a 83; a 143; a 75; a 43

carrasco, J. a 119; a 122

carvalho, M. a 137; a 138

carvalho, s. a 86; a 32

castillo, M. a 77

catarino, a. a 38

cavenaghi, V. a 124; a 101; a 41

ceragioli, h. a 165

cerqueira, d. a 29; a 30

cervantes- llanos, M. a 95; a 76; a 81

christo, P. a 135; a 28; a 47; a 93; a 5

cintado- Benítez, a. a 76; a 95

claudino, R. a 83

clemente, h. a 107

cohen, J. a 90

comini-Frota, e. a 138; a 83; a 137

concha, c. a 119; a 120; a 121; a 63; a 122

conte, l. a 119; a 120; a 121; a 63

conte, R. a 122

cores, e. a 100; a 99

cores, V. a 8 correa, e. a 83; a 138

correale, J. a 160; a 90; a 34; a 98; P 3

correia, F. a 91

cossío, M. a 95

costa, J. a 134

costa, M. a 113

couto, R. a 115; a 84

cristiano, e. a 160; a 11; a 13; a 14; a 15; a 42; a 6; a 61; a 78

cruz, a. a 108

cruz, e. a 116; a 77

cruz, l. a 150

cukierman, e. a 103; a 66

cúneo, J. a 48

curbelo, c. a 143; a 75; a 43

cutter, G. a 131

damasceno, a. a 83; a 52

50 51

damasceno, B. a 17; a 18; a 52

dawson, K. a 24; a 46; a 59

defanti, i. a 53

deslandes, M. a 37

dias, R. a 86; a 32

díaz, e. a 83

díaz-argudín, t. a 95

diniz, d. a 156

domingues, R. a 132; a 4; a 54; a 134

doring, t. a 144; a 55; a 132; a 4

ebers, G. a 131

edan, G. a 44

eizaguirre, B. a 100; a 99

elliff, d. a 83

enríquez, F. a 80

escobar, d. a 83

espinoza, s. a 119; a 120; a 121; a 63; a 122

Fajardo, c. a 19

Falcón-cama, V. a 76

Faria, t. a 124; a 101

Farias, a. a 154; a 165; a 52

Farinhas, J. a 31; a 67

Fazzito, M. a 128

Fernandes, a. a 133

Fernandes, e. a 26; a 38

Fernández, o. a 65; a 159; a 23; P 6

Fernández-Masso, J. a 76

Ferreira, M. a 137;a 138;a 152

Ferrer, o. a 116

Fêzer, l. a 138; a 167; a 36; a 40; a 53; a 58; a 96; a 55

Figueiredo, a. a 9; a 10

Fink, M. a 101; a 124

Finkelsztejn, a. a 17;a 18

Fiore, a. a 83

Fiorentini, l. a 8

Fleitas, V. a 118; a 15; a 42

Florentin, s. a 118; a 24; a 46; a 59

Fragoso, Y. a 126; a 137; a 138; a 40; a 2; a 51; a 83; a 36; a 17; a 18

Franco, c. a 83

Freedman, M. a 44

Freitas, M. a 102; a 142

Frider, N. a 160; a 90; a 34

Friedreich, a. a 117

Gallardo, M. a 105; a 50; a 64 Gama, P. a 137; a 138

Garcea, o. a 3; a 8; a 16; a 23; a 7

García, F. a 122

Garcia, Y. a 150Garrahan, J. P 12

Gasparetto, e. a 55; a 132; a 134; a 144; a 4; a 54; a 12; P 19

Georgeto, s. a 137; a 138

Gerber, M. a 162

Ghezzi, a. a 129

Giacomo, M. a 83

Giunta, d. a 160

Glehn, F. a 165; a 52; a 71 Gold, R. a 24;a 46;a 59

Gomes Neto, a. a 135;a 28;a 47;a 93;a 5

Gomes, B. a 141

Gomes, M. a 17; a 18

Gomes, s. a 126; a 137; a 138; a 147; a 51; a 83

Gómez, J. a 68; a 76; a 95; a 81; P 17

Gomez, s. a 50

Gómez-añón, a. a 158

Gonçalves, M. a 123; a 137; a 138; a 51;

a 83; a 126

González, M. a 119; a 120; a 121; a 63; a 122

Gonzalo, h. a 79

Goodin, d. a 131

Gracia, F. a 160

Grass, d. a 95

Grzesiuk, a. a 141; a 83

Guerreiro, c. a 155

Guerrero, M. a 23

Guiu, B. a 79

Gumieiro, B. a 141

Gutfilen, G. a 55

hartung, h. a 44

hauser, s. a 161; a 162

havrdova, e. a 24; a 59

hernandez, F. a 91

herrmann, J. a 44

hobi, c. a 128

horta, W. a 10; a 9

hotermans, c. a 59

inojosa, J. a 83

islas, M. a 160; a 163; a 27; a 45; a 80; a 110

itagiba,V. a 132; a 4

Jiménez, G. a 122

Jorge, F. a 128

Kaimen-Maciel, d. a 104; a 115; a 73; a 83; a 84; a 148; a 35;a 137; a 138

Kallaur, a. a 104; a 115; a 73; a 84; a 148; a 35

Kallembach, J. a 30; a 92

Kappos, l. a 161; a 162; a 90; a 44

Kawagoe, K. a 115; a 84

Kay, c. a 94

Kerszberg, M. a 125

Kira, J. a 168; P 16

Kirchmeyer, c. a 57; a 29

Klajn, d. a 16

Kosac, V. a 31; a 67

Kremenchutzky, M. a 131; P 13

Krupp, l. a 129

Kuperman, G. a 48; a 145

Kurukulasuriya, N. a 24; a 59; a 46 lacativa, M. a 88

lagumersindez-denis, N a 76

langdon, d. a 131

lanius, V. a 44

lavado, e. a 115; a 84

lehr, l. a 129

léllis, B. a 141

león, a. a 23

leon, R. a 127; a 146; a 82

leppert, d. a 161; a 162

levya, l. a 65

li, d. a 161

liguori, N. a 3; a 8; a 16; a 23; a 7

lima, a. a 109; a 57

lima, M. a 112

lin, K. a 83

linhares, u. a 97; a 38

longhini, a. a 154; a 52 lopategui-cabeza, i. a 81

lopes, F. a 39; a 132; a 134; a 144; a 4; a 12; a 54; a 55

lopes, J. a 104; a 115;a 137; a 138; a 148; a 73; a 83;a 84; a 35

lopes, K. a 32

lópez, e. a 80

lópez-saura, P. a 81

52 53

lorenzoni, P. a 94

lourenço, G. a 36; a 40; a 58; a 83

luetic, G. a 90

luis s Nali a 124

lyrio, M. a 133; a 114

Machado, M. a 152

Machado, s. a 123

Machnicki, G. a 160; a 34; a 48

MacManus, d. a 46

Magalhães, e. a 117; a 56; a 70

Malfetano, F. a 144; a 54; a 138; a 36; a 40; a 58; a 9; a 96; a 10

Mandler, R. P 14

Marcilla, M. a 48 Marin, K. a 26; a 38

Marinho, P. a 102; a 142

Martinez, a. a 83; a 75; a 143

Martínez, a. a 43

Martínez, F. a 158

Martínez-sánchez, G. a 81

Martins, c. a 144

Masterman, d. a 161

Matheus, N. a 26; a 38

Matos, K. a 19

Matta, a. a 67

Matta,a. a 31

Mciiroy, c. a 129

Medeiros, M. a 115; a 84

Meinel, M. a 129

Meira, i. a 54; a 9; a 58; a 36; a 40; a 10; a 96; a 138

Meirelles, a. a 56

Melamud, l. a 100; a 99

Melcon, M. a 48; a 83; P 2

Melo, P. a 128Meltzer, l. a 59

Mendes, M. a 137; a 138

Mendive, M. a 79

Merino, a. a 8

Merino, P. a 122; a 119; a 120; a 121; a 63

Miguez, J. a 15; a 42

Miller, d. a 44; a 46

Miraldi, F. a 54

Moises, F. a 45; a 80

Molina, o. a 116; a 77; a 127; a 146; a 82

Moll, F. a 166

Montalbán, X. a 44

Monteagudo, a. a 68

Monteiro, t. a 30; a 57

Moraes, a. a 165; a 52; a 154

Moraes, l. a 101; a 128; a 33

Moraga, M. a 129

Moral, e. a 79

Morales, N. a 83

Morales, R. a 138; a 137; a 83

Moreira, a. a 152

Moreira, M. a 83

Moreira, s. a 83

Morimoto. h. a 148; a 73; a 35

Muniz, a. a 137; a 138

Nali, l. a 101; a 33

Nascimento, o. a 67; a 31

Naylor, R. a 90

Nazabal-Galvez, M. a 95; a 76

Neri, V. a 140; a 89; a 38

Netto, s. a 26

Nóbrega Junior, a. a 123

Nóbrega, F. a 32

Nogales-Gaete, J. a 120; a 119; a 121; a 63; a 122

Nogueira, l. a 111; a 139; a 151; a 66

Nogueira, s. a 32

Novas, M. a 24; a 59

Novis, s. a 53; a 167

o-connor, P. a 161

oehninger, c. a 158

oger, J. a 131

oliva, t. a 115

olival, G. a 101; a 124; a 33; a 41

oliveira, a. a 101; a 33

oliveira, e. a 154; a 165

oliveira, F. a 126; a 138; a 83; a 137; a 51; a 147

oliveira, s. a 115; a 84; a 104; a 73; a 35; a 148

oliveira,c. a 83; a 2; a 126; a 137; a 138; a 51

ordaz, e. a 50

ortiz, G. a 45; a 80

otranto, K. a 53

Pace, a. a 59

Paes, R. a 109; a 57; a 29; a 107; a 30 Paiva, c. a 74; a 10; a 9

Pamplona, R. a 79

Panis, c a 104

Paradela, e. a 10; a 9

Paredes, M. a 118

Patrucco, l. a 6; a 13; a 14; a 15; a 42; a 61; a 78; a 11; P 10

Paula, R. a 154; a 165

Pavón-Fuentes, N. a 95

Peçanha Neto, s. P 18

Pedroso-santana, s. a 95

Peixoto, e. a 38

Peixoto, M. a 128

Pelegrino, l. a 104; a 35; a 84

Penna e costa, a. a 117; a 56; a 70

Pentón-arias, e. a 76

Pentón-Rol, G. a 76; a 95; a 81

Peralta, s. a 79

Pereira, a. a 49

Pereira, B. a 83

Pereira, d. a 19

Pereira, F. a 49; a 74 Pereira, V. a 144; a 9; a 36; a 40; a 10; a 58; a 88; a 96

Pereira, W. a 115; a 84; a 104; a 73; a 35; a 148

Pérez, a. a 53 Pessôa, F. a 134; a 12

Peterlevitz, a. a 165

Phillips, J. a 24; a 59

Piccolo, a. a 153; a 20

Pimentel, M. a 53; a 167

Pinto, l. a 26

Pinto, s. a 106

Pires, c. a 55 Pleimes, d. a 44

Pohl, d. a 129

Pohl,c. a 44

Polman, c. a 44

Portero-otin, M. a 79

Pradella, F. a 154; a 165; a 60; a 71

Prado, F. a 31

Quero, c. a 56; a 70

54 55

Raghupathi, K. a 24

Rametta, M. a 131

Ramirez, V. a 45

Ramos, J. a 80

Ravelo, M. a 127; a 146; a 82

Reder, a. a 131

Reich, e. a 125

Reiche, e. a 115; a 84; a 104; a 73; a 35; a 148

Resk, M. a 48

Ribeiro, a. a 114

Ribeiro, J. a 83

Ribeiro, s. a 126; a 51; a 83

Rios, G. a 91

Ritter, s. a 90

Rivera, J. a 150; a 160

Rocha, c. a 10; a 9

Rocha, M. a 153; a 20

Rodrigues, B. a 38; a 103; a 66

Rodrigues, d. a 57

Rodrigues, M. a 2

Rodríguez, c. a 83

Rojas, G. a 143; a 75; a 43 Rojas, J. a 160; a 11; a 13; a 14; a 15; a 34; a 42; a 6; a 61; a 78; a 48

Rojas, s. a 119; a 121; a 63; a 122

Romano, c. a 101; a 124; a 33 Romano, M. a 160; a 34

Roque, e. a 108

Rosa, a. a 45

Rosalino, J. a 147

Ruiz, l. a 79

Ruiz, M. a 149; a 62; a 75; a 87

Ruocco, h. a 126; a 137; a 51; a 138

Russo, l. a 83

sá, M. a 117

sá, R. a 56

sabino, P. a 111; a 139; a 151; a 66

safanelli, F. a 137; a 138

safanelli, J. a 83

saladino, M. a 16

sales, d. a 133; a 114

salfate, c. a 122; a 119; a 121; a 63

salgado, P. a 137; a 138

salles, R. a 117 salles, t. a 56; a 70

samira apostolos a 128

sanchez, e. a 45

sanchez, J. a 118 sánchez, M. a 80

sandbrink, R. a 44

santana, d. a 70

santiago, t. a 33

santos, c. a 38

santos, G. a 140; a 37; a 136; a 21; a 92; a 30; a 1 ; a 65; a 57; a 38; a 72

santos, l. a 52; a 154; a 165

santos, l. a 111; a 151; a 66

santos, M. a 154; a 165; a 71

santos, s. a 117

sarmento, e. a 49

sassi, R. a 25

sato, d. a 128

satomi, M. a 137; a 138

sauter, a. a 161

scola, R. a 94

seifer, G. a 48

selmaj, K. a 24; a 59

serafim, V. a 101; a 124; a 41

shearer, K. a 83

silva, B. a 8; a 23; a 7; a 3; a 16

silva, c. a 126; a 51

silva, J. a 67

silva, l. a 52

silva, N. a 17; a 18

simão, a. a 104; a 148; a 73; a 35

simm, R. a 101; a 33; a 128

sinnett, M. a 149; a 75; a 87

siqueira, h. a 141

siquineli, F. a 126; a 51; a 83

soto, a. a 105; a 127; a 146; a 50; a 64; a 82; a 116

soto, i. a 127; a 146; a 82; a 77; a 69

souza, a. a 171 souza, l. a 30

souza, R. a 115; a 84; a 135; a 28; a 47; a 5; a 93

spagnol, G. a 154

steinberg, J. a 75; a 143; a 43

stemper, B. a 44

stephan, M. a 46

sumita, l. a 33; a 101; a 124

sweetser, M. a 24

takemoto, M. a 17; a 18

tenembaum, s. a 129; P 12

thomaz, R. a 101; a 124; a 33; a 41

thuler, l. a 133; a 32; a 151; a 111; a 136; a 66; a 30; a 92; a 97

tilbery, c. a 101; a 124; a 33; a 41

tinbergen, J. a 161; a 162

tomic, d. a 90

torres, d. a 19

torres, Y. a 112

trigueros, J. a 108

tukada, d. a 52

umaki, d. a 102; a 142

Valenzuela-silva, c. a 81

Vanotti, s. a 8; a 100; a 85; a 99

Vasconcelos, c. a 140; a 37; a 86; a 32; a 133; a 97; a 32; a 1; a 13; a 38; a 89; a 30; a 57; a 92; a 21; a 49; a 107; a 65; a 74; P 11

Vasquez, l. a 150

Vazquez, t. a 160; a 157; a 150 Velador, e. a 80

Viglietta, V. a 24; a 46

Villa, a. a 48; a 100; P 5

Villalobos, V. a 116; a 77

Villarreal-Barrios, a. a 95

Viridiana, R. a 110; a 163; a 27

Volpini, W. a 165

Vrech, c. a 43; a 143

Werneck, l. a 94

Wilner, N. a 55; a 39

Yang, M. a 24

Yousry, t. a 46

Ysrraelit, c. a 48

Zalcman, J. a 127; a 146; a 82

Zamalloa, c. a 22

Zamorano, V. a 122; a 119; a 121; a 120; a 63

Zhang, R. a 46

Zumaeta, s. a 119; a 121; a 63; a 122; a 120

56 57

ORAL PRESENTATION

NOVEMBER 29th

ABSTRACT ID TITLE

TIME OF PRESENTATION

SESSION ROOM FIRST AUTHOR

A 62

Genetic variability in Peruvian

patients with relapsing remitting

multiple sclerosis, using STR

markers DYS390, DYS391,

DYS392 Y chromosome

15:25 to 15:40

Idiophatic

Inflammatory

demyelinating

Diseases (IIDD) in

Latin America

OrienteMiguel Ernesto Cordova

Ruiz

A 95

Neuromyelitis Optica and Multiple

Sclerosis: A View from DNA, RNA

and Protein Profiles.

15:35 to 15:45

Idiophatic Inflammatory

demyelinating Diseases

(IIDD) in Latin America

Oriente Giselle Penton-Rol

A 63

Geographical distribution of

patients with multiple sclerosis

treated with immunomodulator

at public healthy system in Chile,

2008-2012

15:15 to 15:25

Idiopathic Inflammatory

demyelinating Diseases

(IIDD) in Latin America

Oriente Jorge Elías Nogales-Gaete

A 16

Breastfeeding and risk of

postpartum relapses in women

with multiple sclerosis

17:45 to 17:55

Neuroepidemiology in

MS: Latin American

Studies

Segóvia II Nora Fernández Liguori

A 50

Epidemiology of Multiple Sclerosis

in the island Oo Margarita,

Venezuela

17:55 to 18:05

Neuroepidemiology in

MS: Latin American

Studies

Segóvia II Arnoldo Soto

A 51

Epstein-Barr virus and smoking

habits in Brazilian patients with

multiple sclerosis

18:05 to 18:15

Neuroepidemiology in

MS: Latin American

Studies

Segóvia II Fabio Siquineli

A 52

Epstein-Barr vírus infection of

the central nervous system and

multiple sclerosis disease activity

18:15 to 18:25

Neuroepidemiology in

MS: Latin American

Studies

Segóvia II Carlos Otávio Brandão

A 41

Disease modifying therapy

withdrawal in relapsing-remitting

multiple sclerosis: follow-up of 40

patients.

16:00 to 16:15 HOT TOPICS Segóvia I

Guilherme Sciascia do

Olival; Vitor Breseghello

Cavenaghi; Vitor Serafim;

Rodrigo Barbosa Thomaz;

Charles Peter Tilbery

NOVEMBER 30th

ABSTRACT ID TITLE

TIME OF PRESENTATION

SESSION ROOM FIRST AUTHOR

A 74Inter- and intragenerational study of MS

familial cases in a reference center in the

city of Rio de Janeiro.

15:15 to 15:30 HOT TOPICS Segóvia IMarcos Papais

Alvarenga

A 81Molecular targets involved in

pathogenesis and response to therapy of

Demyelinating diseases

15:30 to 15:45 HOT TOPICS Segóvia IMajel Cervantes-

Llanos

A 124

Research of locus Xq22.3 as transcription

source for endogenous retrovirus and

its association with the multiple sclerosis

etiology

15:45 to 16:00 HOT TOPICS Segóvia IGuilherme Sciascia

do Olival

A 3Acute Disseminated Encephalomyelitis:

Presentation in the adult population.16:30 to 16:40

LACTRIMS Oral

Presentation MSSegóvia III Ricardo Alonso

A 6

Aplication of the Mcdonald 2010 criteria

for the diagnosis of Multiple Sclerosis in

an argentinean cohort of patients with

clinically isolated syndromes

16:40 to 16:50LACTRIMS Oral

Presentation MSSegóvia III Liiana Patrucco

A 21Clinical Analysis of malignant MS in a

brazilian reference center for MS16:50 to 17:00

LACTRIMS Oral

Presentation MSSegóvia III

Fabrício da Costa

Hampshire de

Araújo

A 42Prognostic factors of malignant multiple

Sscleosis in a cohort of argentinean

patients

17:00 to 17:10LACTRIMS Oral

Presentation MSSegóvia III Liliana Patrucco

A 92Multiple Sclerosis: natural history and

prognostic factors in Brazilian patients.17:10 to 17:20

LACTRIMS Oral

Presentation MSSegóvia III

Gutemberg

Augusto Cruz dos

Santos

A 112Prevalence of pseudotumoral

demyelinating lesions in an oncology

reference center

17:20 to 17:30LACTRIMS Oral

Presentation MSSegóvia III

Yasmine Coura

Torres

A 11Brain Atrophy as a non response predictor

to interferon? In Relapsing Remitting

Multiple Sclerosis

17:30 to 17:40LACTRIMS Oral

Presentation MSSegóvia III Juan Ignacio Rojas

A 12

Brain atrophy evaluation in Multiple

Sclerosis patients: a comparison study

with Clinically Isolated Syndrome and

Neuromyelitis Optica

17:40 to 17:50LACTRIMS Oral

Presentation MSSegóvia III

Fernanda Miraldi

Clemente Pessôa

A 35

Cytokine profile in relapsing-remitting

multiple sclerosis patients and the

association with the progression and the

activity of the disease

17:50 to 18:00LACTRIMS Oral

Presentation MSSegóvia III Ana Paula Kallaur

A 54Resting-state functional Magnetic

Resonance Imaging in the assessment of

patients with neuromyelitis optica

17:50 to 18:10 NMO Segóvia IIEmerson Leandro

Gasparetto

58 59

ABSTRACTS ID

TITLE AUTHORDATE OF

PRESENTATIONTV TIME OF

PRESENTANTION

ANERJ 01Disfunção urinária em mulheres com Esclerose múltipla do Rio de Janeiro

(Brasil)

Camila Rodrigues

de AlmeidaNOVEMBER 28th 1 16:00 às 16:10

ANERJ 02

Depressão induzida por interferon: homogeneidade de magnitude de sintomas depressivos somáticos e

cognitivos em estudo prospectivo em pacientes com hepatite C

Lucas Pereira Jorge de Medeiros

NOVEMBER 28th 1 16:10 às 16:20

ANERJ 03Multiple Sclerosis Lesion Heart x

MitoxantroFrancisco T. M. Oliveira

NOVEMBER 28th 1 16:20 às 16:30

ANERJ 04Neuromyelitis Optica X SPECTRUM

manifestation.Franciso T. M. Oliveira

NOVEMBER 28th 2 16:00 às 16:10

ANERJ 05Injuries of neuroimaging neuritis optical

and neuromyelitis optica.Francisco T. M. Oliveira

NOVEMBER 28th 2 16:10 às 16:20

ANERJ 06Terapia infusional com natalizumabe em pacientes com esclerose: desafio

para o enfermeiro no brasil

Fabiana dos S Carolino

Firmo PereiraNOVEMBER 28th 2 16:20 às 16:30

ANERJ 07Programa de treinamento físico como

fator adjuvante no tratamento da esclerose múltipla

Regina Alvarenga

NOVEMBER 28th 3 16:00 às 16:10

ANERJ 08A Forma Benigna da Esclerose Múltipla:

uma revisão sistemática

Thais Conceição Monteiro

NOVEMBER 28th 3 16:10 às 16:20

ANERJ 09Nível sérico de vitamina D em pacientes

com Esclerose Múltipla atendidos na cidade do Rio de Janeiro

Soniza Vieira Alves Leon

NOVEMBER 28th 3 16:20 às 16:30

ANERJ 10 Espectro Neuromielitis OpticaVeronica Fleitas

NOVEMBER 28th 4 16:00 às 16:10

ANERJ 11

Hemianopsia homônima como Sindrome Clinica Isolada com alto poder de conversão para Esclerose

Múltipla em paciente na quinta década de vida. Relato de caso.

Eduardo Cukierman

NOVEMBER 28th 4 16:10 às 16:20

ANERJ 12

Principais efeitos colaterais do uso de Interferon Beta 1a e Interferon Beta 1B subcutâneo nos pacientes com

Esclerose Múltipla da Santa Casa da Misericórdia do Rio de Janeiro.

Wagner Horta

NOVEMBER 28th 4 16:20 às 16:30

ANERJ 13

Elaboração de um questionário para identificar a presença de comorbidades

em uma série de pacientes com Esclerose Múltipla na cidade do Rio de

Janeiro.

Maristela Cavedagne

NOVEMBER 28th 5 16:00 às 16:10

E-POSTER ANERJ PRESENTATION ANERJ 14

Osteoporose em homem de 50 anos com esclerose múltipla forma surto-

remissão. Relato de caso.

Antonio Carlos

Andrade Alvarenga

Filho

NOVEMBER 28th 5 16:10 às 16:20

ANERJ 15Neuro Behçet:Importância do

Diagnóstico Diferencial

Vanderson Carvalho

NeriNOVEMBER 28th 5 16:20 às 16:30

ANERJ 16Arqueopatologia e dados históricos dos defeitos de formação do Tubo Neural

Renato Manganelli Salomão

NOVEMBER 28th 6 16:00 às 16:10

ANERJ 17 Paralisia periodica HipocalemicaFrancisco

T.M.OliveiraNOVEMBER 28th 6 16:10 às 16:20

ANERJ 18

Prevalência de Achados Orofaringoscópicos em Pacientes

com Roncos Noturnos estudados no Hospital Universitário Gaffrée e Guinle

Felipe de Oliveira

FigueiredoNOVEMBER 28th 6 16:20 às 16:30

ANERJ 19Carcinomatose leptomeníngea: relato

de caso

Isabella Cristina Silva

DefantiNOVEMBER 28th 7 16:00 às 16:10

ANERJ 20Paquimeningite em Granulomatose de

Wegener

Antonio Pereira

Gomes NetoNOVEMBER 28th 7 16:10 às 16:20

ANERJ 21Primary vasculitis of the central nervous

system: a case reportTatiane de

Souza PintoNOVEMBER 28th 7 16:20 às 16:30

ANERJ 22

Comparação esportômica do metabolismo de amônia em atletas de elite durante diferentes protocolos de

treinamento e análise de VO2max

André Nascimento Monteiro

NOVEMBER 28th 8 16:00 às 16:10

ANERJ 23Metabolismo de aminoácidos e de

amônia no desenvolvimento da fadiga central. Uma revisão da literatura atual.

Luis Eduardo Viveiros de

CastroNOVEMBER 28th 8 16:10 às 16:20

ANERJ 24

Concentrações plasmáticas de Alanina; Glutamato; Glutamina e metabolismo de amônia durante sessões repetidas de luta em alta intensidade e curta duração. Uma análise esportômica.

Elizabeth Cataldi

NOVEMBER 28th 8 16:20 às 16:30

ANERJ 25O que a população (des)conhece sobre

epilepsiaYara Dadalti

FragosoNOVEMBER 29th 1 16:00 às 16:10

ANERJ 26O número de casos de Epilepsia de

Etiologia Estrutural/Metabólica pode ser diminuído?

Juliane Sauter

DalbemNOVEMBER 29th 1 16:10 às 16:20

ANERJ 27

Tradução, retrotradução e aplicação do questionário de Limoges (França) numa população de pacientes com

diagnóstico de epilepsia na cidade de Eunápolis - Bahia

Pablo Machado Loureiro

NOVEMBER 29th 1 16:20 às 16:30

60 61

ANERJ 28Epilepsia Mioclônica Juvenil ? Relato

em gêmeas univitelínicas

Cláudia Cecília da Silva Rêgo

NOVEMBER 29th 2 16:00 às 16:10

ANERJ 29Epilepsia mioclônica juvenil ?

paradigma entre focal e generalizada ? Relato de caso.

Ana Carolina Gomes Baltar

NOVEMBER 29th 2 16:10 às 16:20

ANERJ 30

Epilepsia Mioclônica Juvenil: auto-percepção de fatores precipitantes de crises X registros ictais de ativações

investigados por vídeo-EEG

Cláudia Cecília da Silva Rêgo

NOVEMBER 29th 2 16:20 às 16:30

ANERJ 31Mioclonias periorais vs Automatismos

orais ? Relato de CasoSoniza Vieira Alves Leon

NOVEMBER 29th 3 16:00 às 16:10

ANERJ 32Percepção dos estudantes de medicina

acerca da epilepsia

JULIANE SAUTER DALBEM

NOVEMBER 29th 3 16:10 às 16:20

ANERJ 33 Doença de Lafora - Relato de casoShaylla Vilas Bôas Vianna

NOVEMBER 29th 3 16:20 às 16:30

ANERJ 34Padrões Periódicos no

Eletroencefalograma: RevisãoMariana

Silva SouzaNOVEMBER 29th 4 16:00 às 16:10

ANERJ 35Padrão Eletroencefalográfico Periódico:

Aspectos Clínicos, Neuroimagem e Evolução

Mariana Silva Souza

NOVEMBER 29th 4 16:10 às 16:20

ANERJ 36Síndrome do Homem Rígido: relato de

casoClarissa N.

SpitzNOVEMBER 29th 4 16:20 às 16:30

ANERJ 37Estudo clínico, polissonografico e do HLA Classe II em uma série de pacientes brasileiros narcolépticos

Andrea Bacelar

NOVEMBER 29th 5 16:00 às 16:10

ANERJ 38

38. Paraplegia Espástica Hereditária (Síndrome de Staümpell Lorrain):

relato de quatro casos em uma mesma família

Vanderson Carvalho

NeriNOVEMBER 29th 5 16:10 às 16:20

ANERJ 39 Sindrome Pos-Poliojose

h.f.rosalinoNOVEMBER 29th 5 16:20 às 16:30

ANERJ 40The response of the Cutaneous Silent

Period in a group of patients with tunnel carpal syndrome.

Joseph Bruno Bidin

BrooksNOVEMBER 29th 6 16:00 às 16:10

ANERJ 41The response of the Cutaneous Silent

Period in a group of patients with diabetes and polineuropathy.

Joseph Bruno Bidin

BrooksNOVEMBER 29th 6 16:10 às 16:20

ANERJ 42Síndrome do Homem Barril como

apresentação secundária a osteoartrose cervical: um relato de caso

Lucas Oliveira Mourão

NOVEMBER 29th 6 16:20 às 16:30

ANERJ 43Mononeuropatia Multipla e Sindrome

Churg StraussJHF.Rosalino NOVEMBER 29th 7 16:00 às 16:10

ANERJ 44

Estudo Sistemático Anátomo-Cirúrgico dos Ramos do Nervo Musculocutâneo para o Músculo Bíceps Braquial: Bases Anatômicas para a Técnica de Oberlin

Ana Caroline Siquara de

SousaNOVEMBER 29th 7 16:10 às 16:20

ANERJ 45Qual é o sintoma mais precocemente relacionado aos tumores malignos do nervo periférico na neurofibromatose?

Roberto Andre

Torres de Vasconcelos

NOVEMBER 29th 7 16:20 às 16:30

ANERJ 46Polirradiculoneuropatia associada

a quadro reacional em hanseníase: Relato de caso

Louise Mara Giesel

NOVEMBER 29th 8 16:00 às 16:10

ANERJ 47Schwannoma do nervo facial ? Relato

de caso e revisão da literatura

Christiano Assis

Buarque Perlingeiro

NOVEMBER 29th 8 16:10 às 16:20

ANERJ 48

Prevalência e características de dor lombar em uma população de

universitários jovens da área da saúde do município de Santos.

Yara Dadalti Fragoso

NOVEMBER 29th 8 16:20 às 16:30

ANERJ 49

Avaliação do tremor do palato mole e laringe através da

fibronasofaringolaringoscopia em pacientes com doença de Parkinson

Daniella Leitão

MendesNOVEMBER 30th 1 16:00 às 16:10

ANERJ 50

Relação do tempo de doença, distúrbios motores e quantidade de

cuidadores em pacientes com Doença de Huntington ? estudo piloto

Rafael Gonzalez de

OliveiraNOVEMBER 30th 1 16:10 às 16:20

ANERJ 51 Mioclônus Palatal - Relato de caso

Carlos Eduardo Dilen da

Silva

NOVEMBER 30th 1 16:20 às 16:30

ANERJ 52

Estudo intergeracional da Doença de Huntington: dificuldades de

aconselhamento genético preventivo em pacientes com alelos de

penetrância reduzida

Luciana de Andrade

AgostinhoNOVEMBER 30th 2 16:00 às 16:10

ANERJ 53 Hiperfagia na Doença de Alzheimer

Marcela Rodrigues Moreira

Guimarães

NOVEMBER 30th 2 16:10 às 16:20

ANERJ 54Deficiency of vitamin B12 and relationship with Neuro-Image

Sidney Gomes

NOVEMBER 30th 2 16:20 às 16:30

ANERJ 55Efeitos da Vitamina K1 na cognição e

memória de ratos SHR-spVictor Agati Cavargere

NOVEMBER 30th 3 16:00 às 16:10

ANERJ 56Rastreio de síndrome frontal pelo frontal Assessment Battery (FAB)

Rafael Neder NOVEMBER 30th 3 16:10 às 16:20

62 63

ANERJ 57

Estudo comparativo entre o comprometimento cognitivo na Síndrome de Sjögren e Esclerose

Múltipla

Dóra-Neide Rodrigues

NOVEMBER 30th 3 16:20 às 16:30

ANERJ 58Características da cefaleia crônica

recorrente em crianças entre cinco e nove anos de idade

Felipe Moreira

GannoumNOVEMBER 30th 4 16:00 às 16:10

ANERJ 59Demographic and Clinical Profile

of Paediatric Patients with Multiple Sclerosis: A Cohort Study

Mar Mendibe

BilbaoNOVEMBER 30th 4 16:10 às 16:20

ANERJ 60

Singular associação de lesão pseudo tumoral cerebral recorrente em

paciente pediátrico com neuromielite óptica anti-AQP4 negativo

Natalia Matheus

Terrana de Carvalho

NOVEMBER 30th 4 16:20 às 16:30

ANERJ 61 Cefaleia NumularSidney Gomes

NOVEMBER 30th 5 16:00 às 16:10

ANERJ 62Revisão sistemática do uso de

metoclopramida endovenosa no tratamento agudo da enxaqueca

Yara Dadalti Fragoso

NOVEMBER 30th 5 16:10 às 16:20

ANERJ 63Bases genéticas de uma caso raro

de X-ALD forma cerebral infantil em menina

Patricia Reche

NOVEMBER 30th 5 16:20 às 16:30

ANERJ 64 Amnesia Global Transitoria

Jose Henrique Fernandes Rosalino

NOVEMBER 30th 6 16:00 às 16:10

ANERJ 65Dissecçoes Arteriais Espontaneas

BilateralFrancisco

T.M.OliveiraNOVEMBER 30th 6 16:10 às 16:20

ANERJ 66

Suplementação de alfa tocoferol no status neurológicos de ratos

espontaneamente hipertensos com propensão ao acidente vascular encefálico (SHRSP) submetidos a

inibição do óxido nítrico (L-name).

Marcela Rodrigues Moreira

Guimarães

NOVEMBER 30th 6 16:20 às 16:30

ANERJ 67A Acupuntura como terapia

coadjuvante na recuperação de seqüelas de acidente vascular cerebral

Marcos Barros

Caldeira de Andrada

NOVEMBER 30th 7 16:00 às 16:10

ANERJ 68Distúrbio da coagulação na doença

cérebrovascular: relato de caso

Sérgio Augusto P.

NovisNOVEMBER 30th 7 16:10 às 16:20

ANERJ 69Ação da Riboflavina na Lesão

Neurológica após Bloqueio da NOS

Camille Feitoza França

NOVEMBER 30th 7 16:20 às 16:30

ANERJ 70Meningite Criptococcica e surdez

súbita reversível : Um relato de caso

Maria Helena de

Araújo MeloNOVEMBER 30th 8 16:00 às 16:10

ANERJ 71 Mielite MeningocócicaTania Regina

Dias Saad Salles

NOVEMBER 30th 8 16:10 às 16:20

ANERJ 72Paralisia Facial Periférica e Anacusia

Como Manifestação Inicial de Neurossífilis

Carlos Eduardo Dilen da

Silva

NOVEMBER 30th 8 16:20 às 16:30

ANERJ 73Encefalite límbica: uma apresentação

atípica de neurossífilis

Juliana Rezende

DutraNOVEMBER 30th 8 16:20 às 16:30

ANERJ 74What do patients know about

pregnancy in multiple sclerosis?

Cristiane Borges Patroclo

NOVEMBER 30th 1 10:00 às 10:10

ANERJ 75Síndrome de tronco cerebral e

encefalopatia como manifestações do espectro NMO.

Erlane Fernandes

NOVEMBER 30th 1 10:10 às 10:20

ANERJ 76Surdez em pacientes com esclerose

múltipla: 3 relatos de caso

Hugo Fraga Barbosa

LeiteNOVEMBER 30th 1 10:20 às 10:30

ANERJ 77

Teste de Identificação Olfativa em Pacientes Submetidos a Lobectomia

Temporal para Tratamento de Epilepsia Temporal Mesial Refratária

Fernando Andreiuolo Rodrigue

NOVEMBER 30th 2 10:00 às 10:10

ANERJ 78

Perda auditiva por exposição continuada a Níveis de Pressão Sonora

Elevada (NPSE): A proteção auditiva adequada como um fator excludente

do nexo laboral

Jorge Barbosa

Leite NOVEMBER 30th 2 10:10 às 10:20

ANERJ 79

Desenvolvimento e implementação de um sistema de banco de dados

relacional para estudo da prevalência de esclerose múltipla no estado do Rio

de Janeiro.

Carlos Alberto Alves

NOVEMBER 30th 2 10:20 às 10:30

THE ABSTRACTS OF THE 79 PAPERS PRESENTED AS E-POSTERS IN THE

5TH CONGRESS OF THE ANERJ ARE PUBLISHED IN THE SUPPLEMENTT OF

THE REVISTA BRASILEIRA DE NEUROLOGIA.

64 65

E-POSTER LACTRIMS PRESENTATION

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 02

A 116REACTIVATION OF DISEASE ACTIVITY IN PATIENTS

WITH MULTIPLE SCLEROSIS AFTER NATALIZUMAB

DISCONTINUATION: A CASE REPORT IN VENEZUELA.

12:30 - 12:40

TREATMENT A 76

INTERFERON BETA AND C-PHYCOCYANIN:

MOLECULAR MECHANISMS ASSOCIATED TO A NEW

COMBINED THERAPY FOR MULTIPLE SCLEROSIS

12:40 - 12:50

Committee: Adriana

Carrá, Juan Bonito

e Charles Tilbery

Secretary: Fabricio da

Costa Araújo

A 82

MONITORING ALGORITHM FOR PATIENTS WITH

MULTIPLE SCLEROSIS THAT INITIATE THERAPY WITH

IMMUNOMODULATORS.

12:50 - 13:00

A 90

COMPARISON OF ORAL FINGOLIMOD WITH

INTERFERON BETA-1A IN TREATMENT OF

RELAPSING-REMITTING MULTIPLE SCLEROSIS:

SUBGROUP ANALYSIS OF THE LATIN-AMERICAN

COHORT IN TRANSFORMS STUDY

13:00 - 13:10

A 101

NEW PREDICTIVE MARKERS FOR NATALIZUMAB-

ASSOCIATED PROGRESSIVE MULTIFOCAL

LEUKOENCEPHALOPATY, PRELIMINARY RESULTS.

13:10 - 13:20

A 138THE PROFILE OF NATALIZUMAB ADVERSE EVENTS IN

PATIENTS WITH MULTIPLE SCLEROSIS13:20 - 13:30

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 03

A 9

ASSOCIATION STUDY IN MULTIPLE SCLEROSIS

(MS): CIITA GENE POLYMORPHISM (RS4774*C)

IN CONJUNCTION WITH THE HLA-DRB1*15:01+

HAPLOTYPE INCREASES THE SUSCEPTIBILITY TO MS.

12:30 - 12:40

GENETICS OF THE IIDD A 10

ASSOCIATION STUDY OF IL7R? (CD127) GENE

POLYMORPHISM (T244I) AND HLA CLASS II WITH

SUSCEPTIBILITY TO MULTIPLE SCLEROSIS IN A

BRAZILIAN SAMPLE

12:40 - 12:50

Committee: Tereza

Corona, Oscar Fernandez

e Doralina Brum

Secretary: André

Figueiredo

A 62

GENETIC VARIABILITY IN PERUVIAN PATIENTS WITH

RELAPSING REMITTING MULTIPLE SCLEROSIS,

USING STR MARKERS DYS390, DYS391, DYS392 Y

CHROMOSOME

12:50 - 13:00

A 65

HIGH FREQUENCY OF HLA ALLELE DRB1*0301

AMONG BRAZILIAN NMO PATIENTS FROM RIO DE

JANEIRO (BRAZIL)

13:00 - 13:10

A 148

TUMOR NECROSIS FACTOR BETA (TNF-?) NCOI

GENETIC POLYMORPHISM IS ASSOCIATED WITH

MULTIPLE SCLEROSIS INDEPENDENTLY OF HLA-

DRB1*

13:10 - 13:20

A 95NEUROMYELITIS OPTICA AND MULTIPLE SCLEROSIS:

A VIEW FROM DNA, RNA AND PROTEIN PROFILES.13:20 - 13:30

NOVEMBER 28 TH

IIDD - ABSTRACTS OF GENETIC EPIDEMIOLOGY AND PHYSIOLOGY

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 01

A 50EPIDEMIOLOGY OF MULTIPLE SCLEROSIS IN THE

ISLAND OF MARGARITA, VENEZUELA12:30 - 12:40

EPIDEMIOLOGY

OF IDIOPATHIC

INFLAMMATORY

DEMYELINATING

DISEASES

A 68IDIOPATHIC INFLAMMATORY DEMYELINATING

DISEASES OF THE CNS IN CUBA12:40 - 12:50

Committee: C. keitzoan,

Walter Rocca, M.

Melcom, Antonio

Pereira Gomes Netto

Secretary: Heloíse

Siqueira

A 83

MONTH OF BIRTH DOES NOT SEEM TO INTERFERE

WITH THE PREVALENCE OF MULTIPLE SCLEROSIS

FOR SOUTH AMERICAN PATIENTS AT LATITUDES

ZERO TO 40 DEGREES

12:50 - 13:00

A 88 MULTIPLE SCLEROSIS IN THE CITY OF RIO DE JANEIRO 13:00 - 13:10

A 131SURVIVAL OUTCOMES AND CAUSE OF DEATH FROM

THE 21-YEAR LONG-TERM FOLLOW-UP STUDY13:10 - 13:20

A 160SYSTEMATIC REVIEW OF MULTIPLE SCLEROSIS IN

LATIN AMERICA13:20 - 13:30

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 04

A 43

EARLY CLINICAL PREDICTORS OF SUSTAINED

DISEASE-ACTIVITY-FREE STATUS IN PATIENTS WITH

RELAPSING-REMITTING MULTIPLE SCLEROSIS

TREATED WITH INTERFERON BETA AND GLATIRAMER

ACETATE

12:30 - 12:40

TREATMENT A 44

EARLY INITIATION OF INTERFERON BETA-1B AFTER

A FIRST CLINICAL EVENT SUGGESTIVE OF MULTIPLE

SCLEROSIS: CLINICAL OUTCOMES AND USE OF

DISEASE-MODIFYING THERAPY FROM THE BENEFIT

EXTENSION STUDY

12:40 - 12:50

Committee: Edgardo

Cristiano, Rodrigo

Thomaz e Elizabeth

Armas Secretary: Ana

Beatriz Pereira

A 45

EFFECT OF FISH OIL ON CYTOKINES, OXIDATIVE

STRESS MARKERS AND PROGRESSION DISABILITY IN

MULTIPLE SCLEROSIS

12:50 - 13:00

A 46

EFFECTS OF ORAL BG-12 (DIMETHYL FUMARATE)

ON MAGNETIC RESONANCE IMAGING (MRI)

OUTCOMES IN RELAPSING?REMITTING MULTIPLE

SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF

THE PHASE 3 DEFINE AND CONFIRM STUDIES

13:00 - 13:10

A 59

GASTROINTESTINAL TOLERABILITY EVENTS IN

RELAPSING?REMITTING MULTIPLE SCLEROSIS (RRMS)

PATIENTS TREATED WITH ORAL BG-12 (DIMETHYL

FUMARATE) IN DEFINE AND CONFIRM

13:10 - 13:20

A 147TREATMENT OF DISEASE DEVIC WITH

PLASMAPHERESIS AND CORTICOID13:20 - 13:30

66 67

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:00-14:00

TV 05

A 51EPSTEIN-BARR VIRUS AND SMOKING HABITS IN

BRAZILIAN PATIENTS WITH MULTIPLE SCLEROSIS12:00 - 12:10

ENVIRONMENTAL/

GENETIC RISK FACTORA 16

BREASTFEEDING AND RISK OF POSTPARTUM

RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS12:10 - 12:20

Committee: Sérgio

Baranzini, Carmen Paiva,

Andrés Villa, Lucia

Vianna, Elizabeth Frota

Secretary : Denise Costa,

Yasmin Coura Torres

A 52

EPSTEIN-BARR VÍRUS INFECTION OF THE CENTRAL

NERVOUS SYSTEM AND MULTIPLE SCLEROSIS

DISEASE ACTIVITY

12:20 - 12:30

A 36ANALYSIS ON NEONATAL NEWBORN RESULTS

AMONG PACIENTS WITH MULTIPLE SCLEROSIS12:30 - 12:40

A 104

OXIDATIVE STRESS IN RELAPSING-REMITTING

MULTIPLE SCLEROSIS PATIENTS IN CLINICAL

REMISSION: ASSOCIATION WITH EXPANDED

DISABILITY STATUS SCALE

12:40 - 12:50

A 40DETERMINING FACTORS IN DELIVERY ROUTE

AMONG MULTIPLE SCLEROSIS PATIENTS12:50 - 13:00

A 124

RESEARCH OF LOCUS XQ22.3 AS TRANSCRIPTION

SOURCE FOR ENDOGENOUS RETROVIRUS AND

ITS ASSOCIATION WITH THE MULTIPLE SCLEROSIS

ETIOLOGY

13:00 - 13:10

A 126SERUM LEVELS OF VITAMIN D IN BRAZILIAN

PATIENTS WITH MULTIPLE SCLEROSIS13:10 - 13:20

A 154

VITAMIN D3-INDUCED IDO+ TOLEROGENIC

DCS REDUCES THE SEVERITY OF EXPERIMENTAL

AUTOIMMUNE ENCEPHALOMYELITIS13:20 - 13:30

A 137THE PROFILE OF JCV IN BRAZILIAN PATIENTS WITH

MULTIPLE SCLEROSIS USING NATALIZUMAB13:30 - 13:40

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 06

A 3ACUTE DISSEMINATED ENCEPHALOMYELITIS:

PRESENTATION IN THE ADULT POPULATION.12:30 - 12:40

IIDD - FEATURES IN AL A 112PREVALENCE OF PSEUDOTUMORAL DEMYELINATING

LESIONS IN AN ONCOLOGY REFERENCE CENTER12:40 - 12:50

Committee: Fernando

Bedoy, Jorge Nogales

e Vladimiro Sinay

Secretary: Renato

Salomão

A 77UNUSUAL PRESENTATION OF ACUTE HEMORRHAGIC

LEUKOENCEPHALITIS: A CASE REPORT12:50 - 13:00

A 105PARKINSONISM SECONDARY TO PROGRESSIVE

MULTIPLE SCLEROSIS13:00 - 13:10

A 130 FATIGUE AND DISABILITY 13:10 - 13:20

A 147TREATMENT OF DISEASE DEVIC WITH

PLASMAPHERESIS AND CORTICOID13:20 - 13:30

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 07

A 18

BURDEN OF MULTIPLE SCLEROSIS AND

UNMET NEEDS IN BRAZIL: WORK STATUS AND

PRODUCTIVITY LOSS.

12:30 - 12:40

DRUGS AND ECONOMY A 121

RELAPSING REMITTING MULTIPLE SCLEROSIS (RR-

MS.) IN CHILE. DESCRIPTION OF SOCIOECONOMIC

ASPECTS AND IMPACT OF THE COST OF DRUG

THERAPY IN COMPLEX PATIENTS BARROS LUCO

(CABL).

12:40 - 12:50

Committee: Oscar

Gamarra, Miguel

Cordoba e Cezar Caparo

Secretary: Mauricio

Borges

A 17

BURDEN OF MULTIPLE SCLEROSIS AND UNMET

NEEDS IN BRAZIL: PATIENT PREFERENCES FOR MS

TREATMENTS

12:50 - 13:00

A 34

COSTS OF MULTIPLE SCLEROSIS IN LATIN AMERICA

AND THE CARIBBEAN: SYSTEMATIC REVIEW OF THE

LITERATURE

13:00 - 13:10

A 37

DEMOGRAPHIC AND CLINIC CHARACTERISTICS

OF PATIENTS TREATED WITH NATALIZUMAB ? A

BRAZILIAN PRELIMINARY STUDY.

13:10 - 13:20

A 41

DISEASE MODIFYING THERAPY WITHDRAWAL

IN RELAPSING-REMITTING MULTIPLE SCLEROSIS:

FOLLOW-UP OF 40 PATIENTS.

13:20 - 13:30

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 08

A 48ENCOMS: TREATMENT EXPERIENCE, BURDEN, AND

UNMET NEEDS IN12:30 - 12:40

TREATMENT, DRUGS AND

ECONOMYA 63

GEOGRAPHICAL DISTRIBUTION OF PATIENTS

WITH MULTIPLE SCLEROSIS TREATED WITH

IMMUNOMODULATOR AT PUBLIC HEALTHY SYSTEM

IN CHILE, 2008-2012

12:40 - 12:50

Committee: Carlos

Cuevas, Raul Arcega

e Yara Fragoso

Secretary: Camille França

A 145

TREATMENT EXPERIENCE, BURDEN, AND UNMET

NEEDS (ENCOMS) IN MULTIPLE SCLEROSIS STUDY:

THE COSTS OF MS PATIENTS IN ARGENTINA

12:50 - 13:00

A 110

POSITIVE PREDICTORS OF DRUG ADHERENCE IN

A SAMPLE OF MEXICAN PATIENTS WITH MULTIPLE

SCLEROSIS

13:00 - 13:10

A 58

FREQUENCY OF POSITIVITY IN JCV TESTING IN A

MS COHORT OF PATIENTS AND FOLLOW UP AFTER

NATALIZUMAB TREATMENT

13:10 - 13:20

A 41

DISEASE MODIFYING THERAPY WITHDRAWAL

IN RELAPSING-REMITTING MULTIPLE SCLEROSIS:

FOLLOW-UP OF 40 PATIENTS.

13:20 - 13:30

68 69

NOVEMBER 29 TH

ABSTRACTS ON MS, CLINIC, INVESTIGATION, RADIOLOGY AND TREATMENT

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 01

A 136

THE LONG TERM CLINICAL COURSE OF RELAPSING-

REMITTING MS: PROGNOSIS FACTORS IN BRAZILIAN

POPULATION

12:30 - 12:40

NATURAL HISTORY OF

MSA 21

CLINICAL ANALYSIS OF MALIGNANT MS IN A

BRAZILIAN REFERENCE CENTER FOR MS12:40 - 12:50

Committee: Marcelo

Kremenchutzky,

Marco Moreira e

Claudia Vasconcelos

Secretary: Juliana Calvet

A 23

CLINICAL COMPARATIVE STUDY BETWEEN TWO

MULTIPLE SCLEROSIS CENTRES IN SPAIN AND

ARGENTINA

12:50 - 13:00

A 25CLINICAL FEATURES AND MULTIPLE SCLEROSIS

EPIDEMIOLOGICAL IN RIO GRANDE-RS.13:00 - 13:10

A 42PROGNOSTIC FACTORS OF MALIGNANT MULTIPLE

SCLEOSIS IN A COHORT OF ARGENTINEAN PATIENTS13:10 - 13:20

A 74

INTER- AND INTRAGENERATIONAL STUDY OF MS

FAMILIAL CASES IN A REFERENCE CENTER IN THE

CITY OF RIO DE JANEIRO.

13:20 - 13:30

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 02

A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN

RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.12:30 - 12:40

NATURAL HISTORY OF

MSA 87

MULTIPLE SCLEROSIS IN PATIENTS OF ETHNIC

SHIPIBO CONIBO IN PERU12:40 - 12:50

Committee: Liliane

Patrucco, Andrés Villa

e Fabíola Malfetano

Secretary: Sandra Garcia

A 92MULTIPLE SCLEROSIS: NATURAL HISTORY AND

PROGNOSTIC FACTORS IN BRAZILIAN PATIENTS.12:50 - 13:00

A 118 UNIT REGISTRATION DEMYELINATING DISEASES 13:00 - 13:10

A 119

RELAPSING REMITTING MULTIPLE SCLEROSIS (RR-

MS) IN CHILE. CLINICAL CHARACTERIZATION OF

PATIENTS TREATED WITH IMMUNOMODULATORS, IN

THE PUBLIC SYSTEM, 2008-2012.

13:10 - 13:20

A 127CLINICALLY ISOLATED SYNDROME: STUDY IN

VENEZUELAN PATIENTS13:20 - 13:30

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 03

A 30

COGNITIVE IMPAIRMENT AND MRI FEATURES

IN BENIGN MULTIPLE SCLEROSIS: PRELIMINARY

RESULTS.

12:30 - 12:40

FATIGUE, COGNITION

AND MSA 78

JUXTACORTICAL LESION VOLUME AND COGNITIVE

PERFORMANCE IN EARLY ONSET RELAPSING

REMITTING MULTIPLE SCLEROSIS PATIENTS

12:40 - 12:50

Committee:

Miguel Macias,

Fernanda Mendes

e Damácio Ramon

Secretary: Simone Batista

A 8

ASSOCIATION BETWEEN CLINICAL PARAMETERS

AND COGNITIVE PERFORMANCE IN RELAPSING-

REMITTING MULTIPLE SCLEROSIS IN BUENOS AIRES

12:50 - 13:00

A 27COGNITION AND PERSONALITY IN A SAMPLE OF

MEXICAN PATIENTS WITH MS.13:00 - 13:10

A 28 COGNITION IN MULTIPLE SCLEROSIS 13:10 - 13:20

A 29COGNITION IN THE INITIAL STAGE OF MULTIPLE

SCLEROSIS ? A PRELIMINARY STUDY13:20 - 13:30

A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN

RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.13:30 - 13:40

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 04

A 2A ROLE FOR THE BLINK REFLEX TEST IN THE

DIAGNOSIS AND PROGRESSION OF DISEASE

ASSESSMENT IN MULTIPLE SCLEROSIS.

12:30 - 12:40

COGNITION,

PSYCHOLOGY AND

WALKING

A 111PREDICTIVE FACTORS FOR LOWER WALKING SPEED

IN PERSONS WITH MULTIPLE SCLEROSIS12:40 - 12:50

Committee: Fernando

Cárceres, Miguel Macias

e Alfredo Damasceno

Secretary: Andrea Bacelar

A 155

WALKING DISTANCES COMPARISON BETWEEN

1-MINUTE INTERVALS OF 6-MINUTES WALK TEST IN

MULTIPLE SCLEROSIS PATIENTS

12:50 - 13:00

A 107PERFORMANCE OF PATIENTS WITH MULTIPLE

SCLEROSIS IN D2 TEST13:00 - 13:10

A 109PERSONALITY AND MULTIPLE SCLEROSIS - A

PRELIMINARY STUDY13:10 - 13:20

A 120

RELAPSING REMITTING MULTIPLE SCLEROSIS (RR-MS)

IN CHILE. THE SIX-MINUTE WALKING TEST IN THE

COMPLEX CARE PATIENTS BARROS LUCO (CABL)

13:20 - 13:30

A 125 SELF AWARENESS AND ANOSOGNOSIA IN MULTIPLE SCLEROSIS. 13:30 - 13:40

A 151VALIDITY AND RELIABILITY OF BRAZILIAN VERSION OF THE

MULTIPLE SCLEROSIS WALKING SCALE (MSWS-12)13:40 - 13:50

70 71

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 05

A 103OPTIC NEURITIS FREQUENCY IN PATIENTS WITH

MULTIPLE SCLEROSIS12:30 - 12:40

IIDD: FEATURES IN AL A 6

APLICATION OF THE MCDONALD 2010 CRITERIA

FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS IN

AN ARGENTINEAN COHORT OF PATIENTS WITH

CLINICALLY ISOLATED SYNDROMES

12:40 - 12:50

Committee: Luis Melges,

Isabella D'Andrea Meira

e Carlos Oheringer

Secretary: Wagner Horta

A 7APPLICATION OF 2010 CRITERIA MCDONALD IN A

CLINICALLY ISOLATED SYNDROMES GROUP IN BUENOS AIRES12:50 - 13:00

A 22

CLINICAL AND RADIOLOGICAL CHARACTERISTICS

OF PATIENTS WITH MS IN THE NATIONAL POLICE

HOSPITAL 2000-2010, LIMA – PERU

13:00 - 13:10

A 108PERIMETRIC AND FUNDOSCOPIC FINDINGS IN PATIENTS

WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON13:10 - 13:20

A 64HEMIFACIAL SPASM AS THE FIRST CLINICAL

MANIFESTATION OF MULTIPLE SCLEROSIS13:20 - 13:30

A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN

RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.13:30 - 13:40

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 06

A 57

FREQUENCY OF COGNITIVE CHANGES IN THREE

CLINICAL COURSES OF MULTIPLE SCLEROSIS:

RELAPSING/REMITTING, PRIMARY PROGRESSIVE AND

BENIGN, USING A BRIEF NEUROPSYCHOLOGICAL

SCREENING BATTERY

12:30 - 12:40

COGNITION, PAIN,

FATIGUE, DYSPHAGIA

AND SLEEP

A 66COGNITIVE INFLUENCE ON WALKING OF MULTIPLE SCLEROSIS

PATIENTS IN THE ABSENCE OF CLINICAL DISABILITY12:40 - 12:50

Committee: Renata

Paes, Guillermo Gomez

e Jorge Nogales

Secretary: Helcio

Alvarenga Filho

A 67

IDENTIFYING PAIN IN MULTIPLE SCLEROSIS:

PRELIMINARY RESULTS FROM A STUDY IN A

TERTIARY CENTER

12:50 - 13:00

A 84MOOD DISORDERS AND FATIGUE AMONG MULTIPLE

SCLEROSIS PATIENTS13:00 - 13:10

A 85

MULTICENTER STUDY TO ASSESS COGNITIVE AND

NEUROPSYCHIATRIC DISORDERS IN MULTIPLE

SCLEROSIS PATIENTS FROM LATIN AMERICA

-RELACCEM STUDY: LONGITUDINAL ANALYSIS

13:10 - 13:20

A 115SLEEP QUALITY AND DISEASE PROGRESSION

AMONG MULTIPLE SCLEROSIS PATIENTS13:20 - 13:30

A 102

NMO AND NMO COMPLEX: FREQUENCY OF NMO-

IGG ANTIBODY POSITIVITY IN A REHABILITATION

HOSPITAL IN BRASILIA - BRASIL

13:30 - 13:40

A 133

SYMPTOMS OF OROPHARYNGEAL DYSPHAGIA IN

MULTIPLE SCLEROSIS: PREVALENCE AND CLINICAL

FINDINGS IN A BRAZILIAN POPULATION13:40 - 13:50

A 122

RELAPSING REMITTING MULTIPLES SCLEROSIS (RR-

MS) IN CHILE. EVOLUTION OF DYSPHAGIA AND

DYSARTHRIA IN 84 PATIENTS13:50 - 14:00

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 07

A 156EPIDEMIOLOGICAL AND CLINICAL

CHARACTERIZATION OF 100 PATIENTS WITH

MULTIPLE SCLEROSIS OF GOIAS

12:30 - 12:40

PEDIATRIC IIDD A 91MULTIPLE SCLEROSIS: A REALITY AS

DEMYELINATING DISEASE IN PEDIATRICS.12:40 - 12:50

Committee: Silvia

Tenembaum, Tania

Saad e Gustavo Valle

Secretary: Simone Cotrim

A 126SERUM LEVELS OF VITAMIN D IN BRAZILIAN

PATIENTS WITH MULTIPLE SCLEROSIS12:50 - 13:00

A 129

SUBCUTANEOUS INTERFERON BETA-1A IN

PAEDIATRIC PATIENTS WITH MULTIPLE SCLEROSIS:

REGIONAL OUTCOMES IN AN INTERNATIONAL

RETROSPECTIVE STUDY (REPLAY)

13:00 - 13:10

A 53 PEDIATRIC CASE OF MULTIPLE SCLEROSIS 13:10 - 13:20

A 117

RECURRENT MYELITIS AND TUMEFACTIVE

SUPRATENTORIAL LESION IN CHILDHOOD:

NEUROMYELITIS OPTICA (NMO)?

13:20 - 13:30

A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN

RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.13:30 - 13:40

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 08

A 72

INFUSION OF NATALIZUMAB IN MULTIPLE

SCLEROSIS:EXPERIMENT REALIZED AT THE LAGOA

HOSPITAL IN RIO DE JANEIRO

12:30 - 12:40

TREATMENT A 76

INTERFERON BETA AND C-PHYCOCYANIN:

MOLECULAR MECHANISMS ASSOCIATED TO A NEW

COMBINED THERAPY FOR MULTIPLE SCLEROSIS

12:40 - 12:50

Committee: Ana Lucia

Brito, Valéria Coelho e

Tharso Adoni Secretary:

Luiz Eduardo Castro

A 82

MONITORING ALGORITHM FOR PATIENTS WITH

MULTIPLE SCLEROSIS THAT INITIATE THERAPY WITH

IMMUNOMODULATORS.

12:50 - 13:00

A 90

COMPARISON OF ORAL FINGOLIMOD WITH

INTERFERON BETA-1A IN TREATMENT OF

RELAPSING-REMITTING MULTIPLE SCLEROSIS:

SUBGROUP ANALYSIS OF THE LATIN-AMERICAN

COHORT IN TRANSFORMS STUDY

13:00 - 13:10

A 101

NEW PREDICTIVE MARKERS FOR NATALIZUMAB-

ASSOCIATED PROGRESSIVE MULTIFOCAL

LEUKOENCEPHALOPATY, PRELIMINARY RESULTS.

13:10 - 13:20

A 117

RECURRENT MYELITIS AND TUMEFACTIVE

SUPRATENTORIAL LESION IN CHILDHOOD:

NEUROMYELITIS OPTICA (NMO)?

13:20 - 13:30

A 86FATIGUE AND MAXIMAL EXERCISE CAPACITY IN

RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.13:30 - 13:40

72 73

NOVEMBER 30 TH

ABSTRACTS ON NMO, CLINIC, INVESTIGATION AND TREATMENT

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 01

A 1

A LONGITUDINAL STUDY OF BRAINSTEM

INVOLVEMENT IN A COHORT OF NMO BRAZILIAN

PATIENTS FROM RIO DE JANEIRO

12:30 - 12:40

NATURAL HISTORY OF

NMOA 26

CLINICAL PROFILE OR RECURRENT /BILATERAL OPTIC

NEURITIS IN PATIENTS FROM RIO DE JANEIRO.12:40 - 12:50

Committee: Maria

Lucia Pimentel, Tarso

Atoni e Ibis Soto

Secretary: Carlos Alberto

Alves

A 113PREVALENCE OF THYROID DYSFUNCTION AND

AUTOIMMUNITY IN PATIENTS WITH NMO12:50 - 13:00

A 96

NEUROMYELITIS OPTICA FREQUENCY IN A COHORT OF

MULTIPLE SCLEROSIS PATIENTS AND OTHER CENTRAL

NERVOUS SYSTEM DEMYELINATING DISEASES

13:00 - 13:10

A 47 ENCEPHALOPATHY IN NEUROMYELITIS OPTICA 13:10 - 13:20

A 94NEUROMYELITIS OPTICA AFTER THYMECTOMY IN A YOUNG

MYASTHENIA GRAVIS PATIENT USING CYCLOSPORINE13:20 - 13:30

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 02

A 4

ADVANCED MRI TECHNIQUES FOR THE EVALUATION OF

DEMYELINATING DISEASES: WHAT IS FOR RESEARCH AND

WHAT IS FOR CLINICAL PRACTICE

12:30 - 12:40

RADIOLOGY IN MS A 13 BRAIN ATROPHY IN RADIOLOGICALLY ISOLATED SYNDROMES 12:40 - 12:50

Committee: José

Cabrera, Fernanda Moll

e Juan Pablo Princich

Secretary: Nádia Araújo

A 14

BRAIN ATROPHY OVER 1 YEAR OF DISEASE ONSET

PREDICTS LONG TERM CLINICAL STATUS IN RELAPSING

REMITING MULTIPLE SCLEROSIS

12:50 - 13:00

A 15BRAIN VOLUME CHANGES MAY PREDICT CONVERSION IN

RADIOLOGICALLY ISOLATED SYNDROMES13:00 - 13:10

A 61GENDER RELATED DIFFERENCES IN ATROPHY AND LESION LOAD

IN MULTIPLE SCLEROSIS PATIENTS IN BUENOS AIRES, ARGENTINA13:10 - 13:20

A 153

VISUAL EVOKED POTENTIALS MEASURE AND

CORRELATION WITH DISABILITY PROGRESSION (EDSS)

IN RELAPSING?REMITTING (RRMS) AND SECONDARY

PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)

13:20 - 13:30

A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 04

A 11

BRAIN ATROPHY AS A NON RESPONSE PREDICTOR TO

INTERFERON ? IN RELAPSING REMITTING MULTIPLE

SCLEROSIS

12:30 - 12:40

TREATMENT OF MS AND

NMOA 150

USE OF RITUXIMAB IN DEVIC´S DISEASE, TWO YEARS

FOLLOW UP. MEXICAN EXPERIENCE.12:40 - 12:50

Committee: Adriana

Carrá, Suzana Machado

e Patricio Abad

Secretary: Jorge Leite

A 24

CLINICAL EFFICACY AND SAFETY OF ORAL BG-12

(DIMETHYL FUMARATE) IN RELAPSING?REMITTING

MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS

OF THE PHASE 3 DEFINE AND CONFIRM STUDIES

12:50 - 13:00

A 83MONTH OF BIRTH DOES NOT SEEM TO INTERFERE WITH

THE PREVALENCE OF MULTIPLE SCLEROSIS FOR SOUTH

AMERICAN PATIENTS AT LATITUDES ZERO TO 40 DEGREES

13:00 - 13:10

A 89CEREBROSPINAL FLUID FINDINGS IN A SERIES OF CASES OF

NEUROMYELITIS OPTICA AND MULTIPLE SCLEROSIS: PRIMARY

PROGRESSIVE AND RELAPSING REMITTING FORMS.

13:10 - 13:20

A 79LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS REVEALS

PROTEIN LIPOXIDATIVE DAMAGE AS A POTENTIAL

PATHOGENIC MECHANISM.

13:20 - 13:30

A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 03

A 60

G-CSF ENHANCES FOXP3+ T LYMPHOCYTES AND

MODIFIES THE PROINFLAMMATORY RESPONSE IN

EXPERIMENTAL AUTOIMMUNE NEURITIS

12:30 - 12:40

IIDD IMUNOLOGY

BIOMARKERSA 81

MOLECULAR TARGETS INVOLVED IN PATHOGENESIS AND

RESPONSE TO THERAPY OF DEMYELINATING DISEASES12:40 - 12:50

Committee: Jorge

Correale, Soniza Leon

e Elizabeth Frota

Secretary: Ulisses

Linhares

A 70IMMUNOLOGIC MARKERS VS. THERAPEUTIC HANDLING

OF MULTIPLE SCLEROSIS DURING CHILDHOOD12:50 - 13:00

A 71

IN VIVO ADMINISTRATION OF TLR AGONIST REDUCES

THE SEVERITY OF EXPERIMENTAL AUTOIMMUNE

ENCEPHALOMYELITIS. THE ROLE OF PLASMACYTOID

DENDRITIC CELLS AND B LYMPHOCYTES

13:00 - 13:10

A 73INSULIN RESISTANCE IS ASSOCIATED WITH DISABILITY IN

MULTIPLE SCLEROSIS PATIENTS13:10 - 13:20

A 79

LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS REVEALS

PROTEIN LIPOXIDATIVE DAMAGE AS A POTENTIAL

PATHOGENIC MECHANISM.

13:20 - 13:30

A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40

74 75

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 05

A 32

COMPARISON OF FATIGUE AND FUNCTIONAL

STATUS AMONG MULTIPLE SCLEROSIS SUBTYPES

AND NEUROMYELITIS OPTICA

12:30 - 12:40

FATIGUE AND

COGNITIONA 99

NEUROMYELITIS OPTICA: SEARCHING FOR A

COGNITIVE PATTERN12:40 - 12:50

Committee: Fernando

Gracia, Elias Engelhart,

Patricio Abad and Maria

Fernanda Mendes

Secretary: Mariana

Deslandes

A 100NEUROMYELITIS OPTICA: THE NEED TO

UNDERSTAND PATIENTS´ QUALITY OF LIFE12:50 - 13:00

A 139THE RELATIONSHIP BETWEEN FATIGUE AND GAIT IN

PATIENTS WITH MULTIPLE SCLEROSIS13:00 - 13:10

A 114

PROFILE OF THE ORAL AND PHARYNGEAL PHASES

OF SWALLOWING IN PATIENTS WITH MULTIPLE

SCLEROSIS: PRELIMINARY ANALYSIS

13:10 - 13:20

A 79

LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS

REVEALS PROTEIN LIPOXIDATIVE DAMAGE AS A

POTENTIAL PATHOGENIC MECHANISM.

13:20 - 13:30

A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 06

A 93NEUROMYELITIS OPTICA AND ANTIBODY ANTIAQUAPORIN

4: THE EXPERIENCE OF CAPPEM-BH12:30 - 12:40

ANTI AQP4 IN

SYNDROMES OF NMO

COMPLEX

A 102

NMO AND NMO COMPLEX: FREQUENCY OF NMO-

IGG ANTIBODY POSITIVITY IN A REHABILITATION

HOSPITAL IN BRASILIA - BRASIL

12:40 - 12:50

Committee: Cleonice

Bento. Maria Cristina

del Negro Freitas e

Patricia Beatriz Marinho

Secretary: Luciana

Agostinho

A 152

VALUE OF AQUAPORIN-4 ANTIBODY NMO-IGG AT

THE DIAGNOSIS OF CIS, MS AND NMO SPECTRUM

IN PERNAMBUCO, BRAZIL

12:50 - 13:00

A 5ANTI-AQUAPORIN 4 ANTIBODY POSITIVE AND

PROGRESSIVE DISEASE13:00 - 13:10

A 97

FREQUENCY OF ANTI-AQP4 ANTIBODY IN PATIENTS

WITH NEUROMYELITIS OPTICA AND OPTIC SPINAL

MULTIPLE SCLEROSIS

13:10 - 13:20

A 79

LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS

REVEALS PROTEIN LIPOXIDATIVE DAMAGE AS A

POTENTIAL PATHOGENIC MECHANISM.

13:20 - 13:30

A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 07

A 12

BRAIN ATROPHY EVALUATION IN MULTIPLE

SCLEROSIS PATIENTS: A COMPARISON STUDY

WITH CLINICALLY ISOLATED SYNDROME AND

NEUROMYELITIS OPTICA

12:30 - 12:40

RESONANCE AND NMO A 54

RESTING-STATE FUNCTIONAL MAGNETIC

RESONANCE IMAGING IN THE ASSESSMENT OF

PATIENTS WITH NEUROMYELITIS OPTICA

12:40 - 12:50

Committee: José

Cabrera, J Rivera Flores

and Maria Sheila Rocha

Secretary: Marcela

Guimarães

A 55

EVALUATION OF MICROSTRUCTURAL BRAIN

WHITE MATTER DAMAGE IN PATIENTS WITH

NEUROMYELITIS OPTICA AND MULTIPLE SCLEROSIS

12:50 - 13:00

A 132

SWI PHASE VALUES OF THE WHOLE GRAY AND

WHITE MATTER IN PATIENTS WITH MULTIPLE

SCLEROSIS AND NEUROMYELITIS OPTICA: A

COMPARATIVE STUDY WITH CONTROLS

13:00 - 13:10

A 134

THE CERVICAL SPINAL CORD IN NEUROMYELITIS OPTICA

PATIENTS: A COMPARATIVE STUDY WITH MULTIPLE

SCLEROSIS USING DIFFUSION TENSOR IMAGING

13:10 - 13:20

A 144TRACT BASED SPATIAL STATISTICS (TBSS) IN THE

EVALUATION OF PATIENTS WITH NEUROMYELITIS OPTICA.13:20 - 13:30

A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40

SESSION TV ABSTRACT ID TITLE TIME OF PRESENTATION

12:30-14:00

TV 08

A 138THE PROFILE OF NATALIZUMAB ADVERSE EVENTS IN

PATIENTS WITH MULTIPLE SCLEROSIS12:30 - 12:40

TRATMENT A 143

THE SUSTAINED DISEASE ACTIVITY FREE STATUS AS

MEASURE OF THERAPEUTIC RESPONSE & THE LONG TERM

IMPACT OF IMMUNOMODULATORY TREATMENT

12:40 - 12:50

Committee: Amilton

Barreira, Patricio Abad

e Alina Quevedo

Secretary: Giselle

Lourenço

A 146TREATMENT FAILURE IN MULTIPLE SCLEROSIS:

VECTRIMS CRITERIA12:50 - 13:00

A 116

REACTIVATION OF DISEASE ACTIVITY IN PATIENTS

WITH MULTIPLE SCLEROSIS AFTER NATALIZUMAB

DISCONTINUATION: A CASE REPORT IN VENEZUELA.

13:00 - 13:10

A 134

THE CERVICAL SPINAL CORD IN NEUROMYELITIS

OPTICA PATIENTS: A COMPARATIVE STUDY WITH

MULTIPLE SCLEROSIS USING DIFFUSION TENSOR

IMAGING

13:10 - 13:20

A 144TRACT BASED SPATIAL STATISTICS (TBSS) IN THE

EVALUATION OF PATIENTS WITH NEUROMYELITIS OPTICA.13:20 - 13:30

A 39 DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS 13:30 - 13:40

THE ABSTRACTS OF THE 7TH CONGRESS OF LACTRIMS-RIO 2012 ARE

PUBLISHED IN MULTIPLE SCLEROSIS JOURNAL, 2012. 18 (55)

76 77

78 79

BETAFERON® - BETAINTERFERONA 1B - REG. MS – 1.0020.0080INDICAÇÕES - PACIENTES COM UM ÚNICO EVENTO CLÍNICO SUGESTIVO DE ESCLEROSE MÚLTIPLA (SÍNDROME CLINICAMENTE ISOLADA) - PARA RETARDAR A PROGRESSÃO À ESCLEROSE MÚLTIPLA DEFINIDA. ESCLEROSE MÚLTIPLA RECORRENTE-REMITENTE (EMRR). ESCLEROSE MÚLTIPLA SECUNDÁRIA PROGRESSIVA (EMSP). CONTRAINDICAÇÕES: BETAFERON® (BETAINTERFERONA 1B) É CONTRAINDICADO EM PACIENTES COM HISTÓRIA DE HIPERSENSIBILIDADE À BETAINTERFERONA NATURAL OU RECOMBINANTE OU A QUALQUER EXCIPIENTE DO PRODUTO. CUIDADOS E ADVERTÊNCIAS: A ADMINISTRAÇÃO DE CITOCINAS AOS PACIENTES COM GAMOPATIA MONOCLONAL PRÉ-EXISTENTE FOI ASSOCIADA COM O DESENVOLVIMENTO DE SÍNDROME DE EXTRAVASAMENTO CAPILAR SISTÊMICO, COM SINTOMAS QUE SE ASSEMELHAM AO CHOQUE E EVOLUÇÃO FATAL. PACIENTES QUE VENHAM A SER TRATADOS COM BETAFERON® (BETAINTERFERONA 1B) DEVEM SER INFORMADOS QUE PODEM OCORRER DISTÚRBIOS DEPRESSIVOS E IDÉIAS SUICIDAS COMO EFEITOS SECUNDÁRIOS DO TRATAMENTO, DEVENDO COMUNICAR IMEDIATAMENTE AO MÉDICO A OCORRÊNCIA DESTES SINTOMAS. O MEDICAMENTO DEVE SER ADMI-NISTRADO COM CUIDADO AOS PACIENTES COM HISTÓRIA OU DIAGNÓSTICO DE DISTÚRBIOS DEPRESSIVOS OU COM IDÉIAS SUICIDAS. ESTE PRODUTO CONTÉM ALBUMINA HUMANA E, PORTANTO, EXISTE UM RISCO EXTREMAMENTE REMOTO PARA A TRANSMISSÃO DE DOENÇAS VIRAIS. O RISCO TEÓRICO PARA A TRANSMISSÃO DA DOENÇA DE CREUTZFELD-JACOB É CONSIDERADO TAMBÉM EXTREMAMENTE REMOTO. ALÉM DOS TESTES DE LABORATÓRIO REQUERIDOS NORMALMENTE PARA O MONITORAMENTO DE PACIENTES COM ESCLEROSE MÚLTIPLA, É RECOMENDADA A REALIZAÇÃO DOS SEGUINTES TESTES, ANTES DO INÍCIO E NO PERÍODO APÓS A INTRODUÇÃO DO TRATAMENTO EM INTERVALOS REGULARES, E DEPOIS PERIODICAMENTE NA AUSÊNCIA DE SINTOMAS CLÍNICOS: HEMOGRAMA COMPLETO E LEUCOGRAMA DIFERENCIAL, CONTAGEM DE PLAQUETAS E BIOQUÍMICA DO SANGUE INCLUINDO TESTES DE FUNÇÃO HEPÁTICA ( TGO, TGP E �GT). SÃO RECOMENDADOS TESTES PERIÓDICOS DA FUNÇÃO TIREOIDIANA NOS PACIENTES COM HISTÓRIA DE DISFUNÇÃO DA TIRÓIDE OU COM INDICAÇÃO CLÍNICA. BETAFERON® (BETAINTERFERONA 1B) DEVE SER ADMINISTRADO COM CAUTELA EM PACIENTES COM HISTÓRIA DE CONVULSÕES. DEVE SER UTILIZADO COM CUIDADO EM PACIENTES COM DISTÚRBIOS CARDÍACOS PRÉ-EXISTENTES. MULHERES EM IDADE FÉRTIL DEVEM ADOTAR MEDIDAS CONTRACEPTIVAS APROPRIADAS. NÃO É CONHECIDO SE BETAFERON® (BETAINTERFERONA 1B) PODE CAUSAR LESÃO FETAL QUANDO ADMINISTRADO ÀS MULHERES GRÁVIDAS OU SE PODE AFETAR A CAPACIDADE REPRODUTIVA HUMANA. DEVIDO À OCORRÊNCIA POTENCIAL DE REAÇÕES ADVERSAS GRAVES NOS LACTENTES, DEVE-SE DECIDIR ENTRE A INTERRUPÇÃO DA AMAMENTAÇÃO OU DO TRATAMENTO COM BETAFERON® (BETAINTER-FERONA 1B). EM PACIENTES SUSCETÍVEIS, OS EFEITOS ADVERSOS RELACIONADOS AO SNC ASSOCIADOS COM O USO DE BETAFERON® (BETAINTERFERONA 1B) PODEM INFLUENCIAR A HABILIDADE DE DIRIGIR E UTILIZAR MÁQUINAS. INTERAÇÃO MEDICAMENTOSA: NÃO FORAM REALIZADOS ESTUDOS SISTEM-ATIZADOS DE INTERAÇÃO DE BETAFERON® (BETAINTERFERONA 1B) COM OUTROS MEDICAMENTOS. FOI RELATADO QUE AS INTERFERONAS REDUZEM A ATIVIDADE DE ENZIMAS HEPÁTICAS DEPENDENTES DO CITOCROMO P450 EM SERES HUMANOS E NOS ANIMAIS. DEVE-SE TER CAUTELA QUANDO BETAFERON® (BETAINTERFERONA 1B) É ADMINISTRADO EM COMBINAÇÃO COM MEDICAMENTOS QUE APRESENTAM ESTREITA MARGEM TERAPÊUTICA E SÃO LARGAMENTE DEPENDENTES DO SISTEMA HEPÁTICO CITOCROMO P450 PARA A SUA DEPURAÇÃO. DEVE-SE TER CUIDADO NA ADMINISTRAÇÃO CONCOMITANTE DE MEDICAMENTOS QUE TENHAM EFEITO SOBRE O SISTEMA HEMATOPOIÉTICO. REAÇÕES ADVERSAS: FREQÜENTEMENTE FORAM OBSERVADOS SINTOMAS SEMELHANTES AOS GRIPAIS (FEBRE, CALAFRIOS, ARTRALGIA, INDISPOSIÇÃO GERAL, SUDORESE, CEFALÉIA OU MIALGIA). A OCORRÊNCIA DESTES SINTOMAS DIMINUIU COM O PASSAR DO TEMPO. DE MODO GERAL, RECOMENDA-SE A TITULAÇÃO DA DOSE NO INÍCIO DO TRATAMENTO, A FIM DE AUMENTAR A TOLERABILIDADE AO BETAFERON® (BETAINTERFERONA 1B) (VER ITEM “POSOLOGIA”). SINTOMAS SEMELHANTES AOS GRIPAIS TAMBÉM PODEM SER REDUZIDOS COM A ADMINISTRAÇÃO DE UM ANTIINFLAMATÓRIO NÃO ESTEROIDAL. REAÇÕES NO LOCAL DE INJEÇÃO OCORRERAM FREQÜENTEMENTE APÓS A ADMINISTRAÇÃO DE BETAFERON® (BETAINTERFERONA 1B). VERMELHIDÃO, INCHAÇO, ALTERAÇÃO DE COR, INFLAMAÇÃO, DOR, HIPERSENSIBILIDADE, NECROSE E REAÇÕES NÃO-ESPECÍFICAS FORAM ASSOCIADAS, DE MODO SIGNIFICATIVO, AO TRATAMENTO COM 0,25 MG (8 MILHÕES DE UI) DE BETAFERON® (BETAINTERFERONA 1B). A NECROSE PODE SER EXTENSA E PODE ENVOLVER A FÁSCIA MUSCULAR, ASSIM COMO TECIDO ADIPOSO E, PORTANTO, PODE RESULTAR EM FORMAÇÃO DE CICATRIZ. OCASIONALMENTE SÃO NECESSÁRIOS DEBRIDAMENTO E, MENOS FREQÜENTEMENTE, ENXERTO DE PELE. DE MODO GERAL, A INCIDÊNCIA DE REAÇÕES NO LOCAL DE INJEÇÃO DIMINUIU COM O PASSAR DO TEMPO. O TRATAMENTO COM BETAFERON® PODE ASSOCIAR-SE COM ALTER-AÇÕES HEMATOLÓGICAS (ANEMIA, LEUCOPENIA E TROMBOCITOPENIA) E ALTERAÇÕES HEPATOBILIARES (ALTERAÇÕES DAS ENZIMAS ALANINA AMINOTRANSFERASE E ASPARTATO AMINOTRANSFERASE). ASSIM COMO PARA OUTRAS BETAINTERFERONAS, FORAM RELATADOS CASOS RAROS DE LESÃO HEPÁTICA GRAVE, INCLUINDO FALÊNCIA HEPÁTICA, EM PACIENTES TRATADOS COM BETAFERON® (BETAINTERFERONA 1B). OS EVENTOS MAIS GRAVES FREQÜENTEMENTE OCORRERAM EM PACIENTES QUE UTILIZAVAM OUTROS FÁRMACOS OU SUBSTÂNCIAS HEPATOTÓXICAS OU NA PRESENÇA DE CONDIÇÕES MÉDICAS GRAVES CONCOMITANTES (POR EXEMPLO: DOENÇA MALIGNA COM METÁSTASE, INFECÇÃO GRAVE E SEPTICEMIA, ABUSO DE BEBIDAS ALCOÓLICAS). RARAMENTE O TRATAMENTO COM BETAFERON® FOI ASSOCIADO À DISFUNÇÃO DA TIREÓIDE (HIPO OU HIPERTIROIDISMO); ANOREXIA E CONVULSÃO. ALOPECIA, PRURIDO, URTICÁRIA, MIALGIAS OCORRERAM POUCO FREQUENTEMENTE DURANTE O TRATAMENTO COM BETAFERON®. RARAMENTE OBSERVARAM-SE ALTERAÇÕES MENSTRUAIS E PANCREATITE AGUDA POR HIPERTRIGLICERIDEMIA. POSOLOGIA: O TRATAMENTO COM BETAFERON® (BETAINTERFERONA 1B) DEVE SER INICIADO COM A SUPERVISÃO DE UM MÉDICO EXPERIENTE NO TRATAMENTO DA ESCLEROSE MÚLTIPLA. A DOSE RECOMENDADA DE BETAFERON® (BETAINTERFERONA 1B) É DE 0,25 MG (8 MILHÕES DE UI), CONTIDA EM 1 ML DA SOLUÇÃO RECONSTITUÍDA (VER, EM ANEXO, INSTRUÇÕES DETALHADAS PARA PREPARAÇÃO E ADMINISTRAÇÃO), DEVENDO SER INJETADA POR VIA SUBCUTÂNEA, EM DIAS ALTERNADOS. GERALMENTE, A TITULAÇÃO DA DOSE É RECOMENDADA NO INÍCIO DO TRATAMENTO. OS PACIENTES DEVEM INICIAR O TRATAMENTO COM 0,0625 MG (0,25 ML), POR VIA SUBCUTÂNEA, EM DIAS ALTERNADOS, E AUMENTAR A DOSE GRADUALMENTE PARA 0,25 MG (1,0 ML), EM DIAS ALTERNADOS. O PERÍODO DE TITULAÇÃO PODE SER AJUSTADO DE ACORDO COM A TOLERABILIDADE INDIVIDUAL. VENDA SOB PRESCRIÇÃO MÉDICA.

VENDAS SOB PRESCRIÇÃO MÉDICA. BETAFERON NÃO DEVE SER USADO EM PACIENTES CARDIOPATAS. BETAFERON PODE APRESENTAR INTERAÇÃO MEDICAMENTOSA COM BEBIDAS ALCÓOLICAS. BETAFERON PODE INFLUENCIAR A HABILIDADE DE DIRIGIR E UTILIZAR MÁQUINAS.

Material destinado exclusivamente à classe médica.Para mais informações consulte a bula do produto ou a BAYER S.A -

produtos farmacêuticos. Rua Domingos Jorge, 1100 - São Paulo - SP - CEP: 04779-900

www.bayerpharma.com.br

L.BR.SM.2012-11-19.0365

Anuncio Betaferon_210x297.indd 1 11/21/12 4:19 PM

80

SPONSORS

GOLD

SILVER

BRONZE